

# Exhibit A

09/24/04

**CURRICULUM VITAE****BIOGRAPHICAL**

<b>Name</b>	Saïd M. Sebti	
<b>Birth date</b>	April 3, 1956	
<b>Citizenship</b>	U.S.A.	
<b>Social Security #</b>	138-68-5011	
<b>Business Address</b>	H. Lee Moffitt Cancer Center & Research Institute 12902 Magnolia Drive, SRB3DRDIS Tampa, FL 33612-9497	Telephone: (813) 745-6734 Fax: (813) 745-6748 e-mail: sebti@moffitt.usf.edu
<b>Home Address</b>	8957 Magnolia Chase Circle Tampa, FL 33647	Telephone: (813) 907-0543

---

**EDUCATION AND TRAINING**

<b>Undergraduate</b> 1980	Washington State University Pullman, WA	B.S.	Biochemistry
<b>Graduate</b> 1984	Purdue University W. Lafayette, IN	Ph.D.	Biochemistry
<b>Post-graduate</b> 1985 - 1987	Yale University New Haven, CT	Postdoc.	Pharmacology

**APPOINTMENTS AND POSITIONS**

2002-Present	Associate Director	Pre-Clinical Investigations Moffitt Research Institute H. Lee Moffitt Cancer Center, a Comprehensive, National Cancer Institute-Designated Center Tampa, FL
1996 - Present	Program Leader	Drug Discovery Program H. Lee Moffitt Cancer Center & Research Institute, a Comprehensive, National Cancer Institute-Designated Center Tampa, FL

**appointments and positions...**

2000 - Present	Professor with Tenure	Oncology Department University of South Florida School of Medicine Tampa, FL
1996 – Present	Professor with Tenure	Department of Biochemistry and Molecular Biology University of South Florida School of Medicine Tampa, FL
1996 - Present	Professor with Tenure	Department of Pharmacology and Therapeutics University of South Florida School of Medicine Tampa, FL
1993 – 1996	Associate Professor with Tenure	Department of Pharmacology University of Pittsburgh School of Medicine Pittsburgh, PA
1988 - 1996	Member	Pittsburgh Cancer Institute Pittsburgh, PA
1988 - 1993	Assitant Professor	Department of Pharmacology University of Pittsburgh School of Medicine Pittsburgh, PA
1986 - 1987	Associate Research Scientist	Department of Pharmacology Yale University School of Medicine New Haven, CT
1985 - 1986	Postdoctoral Fellow	Department of Pharmacology Yale University School of Medicine New Haven, CT
1980 - 1984	Graduate Research Assistant	Purdue Biochemistry Program Dept. Medicinal Chemistry Purdue University, School of Pharmacy, W. Lafayette, IN
1978 - 1980	Research Assistant	Department of Chemistry Washington State University Pullman, WA

**MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES**

1983 Rho Chi Pharmacy Honor Society  
1984 Sigma Xi Scientific Society  
1986 American Association for the Advancement of Science (01492527)  
1987 American Association for Cancer Research (4552)  
1998 American Association for Biochemistry and Molecular Biology (12151)

**HONORS AND AWARDS**

1978 International Exchange Award (Washington State University)  
1979 Undergraduate Research Award (National Science Foundation)  
1979 Organic Chemistry Honors Lab  
1980 B.S. cum laude  
1985 Postdoctoral Fellowship Award (Smith Kline and French)  
1989 Junior Faculty Research Award (American Cancer Society)  
1995 National Cooperative Drug Discovery Award (National Cancer Institute)  
1997 Nato Workshop Award  
1999 National Cancer Institute Award from CTEP to conduct biochemical correlative studies for proof-of-concept in phase II clinical trials with farnesyltransferase inhibitors.  
2000 Editor, "Farnesyltransferase Inhibitors in Cancer Therapy" book for Humana Press Inc.  
2000 Guest Editor, Oncogene Review Issue entirely dedicated to New Drug Targets and Therapies for Cancer  
2000 National Cooperative Drug Discovery Award (National Cancer Institute)

**PROFESSIONAL ACTIVITIES**

2004 Member, 2004 AACR Program Committee  
2003 Member, American Cancer Society IRG Review Committee  
2003 Scientific Director, Proteomics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.  
2003 Co-organizer, conference on Molecular Targets for Cancer Therapy, October 2004, St. Petersburg, FL  
2002 Member, Scientific Committee, AACR-NCI-EORTC meeting, Frankfurt, Germany  
2001 Chair & Speaker, plenary session on "Targeting Ras and MAPKs" in "Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications", AACR-NCI-EORTC meeting, Miami, Florida  
2001 Member, Scientific Committee, AACR-NCI-EORTC Meeting, Miami, Florida  
2001 Organizer, Moffitt Cancer Center Research Retreat, Wesley Chapel, Florida  
2001 Chair, Experimental Therapeutics Program Committee, American Association for Cancer Research, Philadelphia, PA  
2000 Co-organized international conference on "New Molecular Targets for Cancer Therapy", St. Petersburg Beach, FL  
2000 Co-organized conference on Cancer Research and Biotechnology in the Florida High Tech Corridor, Tampa, Florida  
2000 Co-chaired minisymposium on "Farnesyltransferase Inhibitors", Annual meeting of American Association for Cancer Research, San Francisco, California  
2000 Chaired, Colon and Lung Cancer Session, Moffitt Cancer Center Research Retreat Tampa, Florida  
1999 Member, Program Committee, American Association for Cancer Research (AACR)  
1999 Co-chaired poster discussion session on "Farnesyltransferase Inhibitors", Annual

- 1998 meeting of American Association for Cancer Research, Philadelphia, Pennsylvania  
Co-chaired mini-symposium on “Farnesyltransferase Inhibitors”, Annual meeting of American Association for Cancer Research, New Orleans, Louisiana
- 1996 - Present Initiated and directed the Drug Discovery Program at the H. Lee Moffitt Cancer Center & Research Institute, a Comprehensive NCI-designated cancer center, Tampa, FL.
- 1997 Organized an International NATO Advanced Research Workshop on “Protein-Protein and Protein-Lipid Interactions in Signal Transduction: Use of Small Synthetic Molecules as Probes and Therapeutic Agents”, Clearwater, FL.
- 1995 Co-chaired mini-symposium on “Targeting Ras”, American Association for Cancer Research, Toronto, Canada
- 1993 - 1996 Initiated and co-directed a Cancer Drug Discovery Program at the University of Pittsburgh, Pittsburgh, PA.
- 1992 - 1994 Founded the Signal Transduction Society of Pittsburgh, Pittsburgh, PA.

### **COMPREHENSIVE NCI CANCER CENTER EXPERIENCE**

- Member of the Moffitt Cancer Center team that strategically planned for submitting core grant application. Successfully prepared and obtained NCI designation and comprehensive status.
- Successfully obtained core grant with basic science, clinical investigations and cancer control programs.
- Member of the team that recruited basic, clinical and cancer control research faculty to grow NCI funding from \$1M in 1996 to OVER \$40M in peer-reviewed funding in 2003.
- Responsible for starting the drug discovery program at Moffitt Cancer Center. Successfully recruited faculty members and stimulated intra- and inter-programmatic interactions that grew funding to \$3.5 million dollars direct costs per year.
- Successfully obtained as PI two program projects that enhanced intra- and inter-programmatic interaction.

### **BENCH TO BEDSIDE EXPERIENCE FROM DRUG DISCOVERY TO HYPOTHESIS-DRIVEN CLINICAL TRIALS**

- Broad experience in drug design, discovery and development from chemistry to clinical investigations.
- As director of drug discovery, stimulated numerous fruitful interactions between chemists, biochemists, cell biologists and pharmacologists as well as interaction between basic scientists and clinical investigators. Areas of successful interactions include p53/mdm2, Akt, STAT3, Bcl2/Bax and pRb/Raf.
- Responsible for starting a core facility for “Real” and “Virtual” High through put screening ( HTS ) and molecular modeling.

- Responsible for the development of farnesyltransferase and geranylgeranyltransferase inhibitors, PDGF and VEGF binders, proteasome inhibitors and STAT3 signaling antagonists as novel anticancer drugs from rational drug design to structure activity relationships to proof-of-principle in cell culture and animals to advanced preclinical studies.
- Responsible for designing with clinical investigators several hypothesis-driven human clinical trials with proof-of-concept using biochemical end points. Successfully conducted and published phase II clinical trials with farnesyltransferase inhibitors in multiple myeloma and myelodysplastic syndrome. Involved in ongoing multiinstitutional clinical trials in melanoma and brain cancer patients.
- Presently leading a team of Basic Scientists, a Clinical Investigator, a Pathologist and a Surgeon in evaluating the clinical and biological activity of the combination treatment of breast cancer patients with the farnesyltransferase inhibitor Zarnestra and the cytotoxic agents AC.
- Responsible for a National Cancer Institute reference laboratory for biochemical correlation studies of clinical trials with the novel antitumor agents, farnesyltransferase inhibitors.

#### TECHNOLOGY TRANSFER/PHARMACEUTICAL ACTIVITIES

- Successfully negotiated and obtained license and research agreements with Abbott Laboratories on the design, synthesis and biological evaluations of farnesyltransferase and geranylgeranyltransferase I inhibitors as novel anticancer drugs.
- Collaborations with Abbott resulted in advancement of farnesyltransferase inhibitors from early to advanced preclinical studies and onto a phase I clinical trial.
- Member of the technology transfer steering committee at the H. Lee Moffitt Cancer Center & Research Institute. Help coordinate technology transfer issues such as licensing agreements, research agreements and spin-off companies.
- Author of 13 issued patents

#### CONSULTING ACTIVITIES

1993	Special reviewer for Experimental Therapeutics Study Section, National Cancer Institute, National Institutes of Health
1995	Reviewer for "The National Cooperative Natural Products Drug Discovery Groups", Study Section, National Cancer Institute, National Institutes of Health
1994 - 1995	Promega Corporation, Madison, WI
1994 - 1995	Biomeasure Inc., Boston, MA
1995 - 1998	Abbott Laboratories, Chicago, IL
1997	Reviewer for Experimental Therapeutics Study Section, National Cancer Institute, National Institutes of Health.
1999	Chair, FTI Clinical Trial panel, Cancer Therapy Evaluation Program, National Cancer Institute
1999	Member, Council of Scientific Advisors, University of Central Florida Cancer

	Center
2000	Member, Cancer Center Core Grant site visit, National Cancer Institute, National Institutes of Health
2000	Member, Advisory Group for Astrazeneca; Farnesyl Transferase Inhibitor preclinical to clinical interface.
2000	Temporary Member, National Cancer Institute Scientific Review Group, Cancer center core grants (parent committee)
2000	Reviewer for the Dutch Cancer Society (Nederlandse Kankerbestrijding)
2000	Reviewer for National Cancer Institute RFA and PA's entitled, "Molecular Target Drug Discovery for Cancer".
2001	Chair, Experimental Therapeutics, Program Committee, American Association for Cancer Research.
2001	Member, Advisory group for Pfizer; Farnesyltransferase inhibitor phase I trial.
2001	Member, Scientific Committee, AACR-NCI-EORTC meeting, Miami, Florida
2001	Member, Tampa Bay Biotech Visioning Session, Tampa, Florida
2001	Member, National Cancer Institute Signal Transduction Working Group
2002	Member, AstraZeneca Advisory Board, Clinical Development of a Farnesyl Transferase Inhibitor
2002	Member, Scientific Committee, AACR-NCI-EORTC meeting, Frankfurt, Germany
2004	Consultant, AstraZeneca UK Ltd.

### TEACHING ACTIVITIES

2001 – present	University of South Florida, Department of Oncology, team taught "Cancer Biology Course"
1997-2000	University of South Florida, Department of Biochemistry and Molecular Biology, team taught "Graduate Biochemistry"
1989 - 1996	University of Pittsburgh, Department of Pharmacology. Organized, directed and team taught "Receptors and Signal Transduction"
1989 - 1996	University of Pittsburgh, Department of Pharmacology. Team taught cancer pharmacology.
1992 - 1996	University of Pittsburgh, Department of Pharmacology. Team taught "Perspectives in Pharmacology"
1992 - 1996	University of Pittsburgh, Department of Neurobiology Anatomy and Cell Science. Team taught "Cell Structure and Function": "Receptors", "Second Messenger Systems and Signal Transduction".
1992 - 1996	University of Pittsburgh First Year Medical School. "Introduction to Chemical Signaling"; "Signal Transduction"; "Oncogenes", "Oncogenes and Signaling"; "Oncogenes as Anticancer Drug Targets"
1988 - 1996	University of Pittsburgh, Department of Pharmacology, Second Year Medical School Pharmacology Course. Taught the following lectures: Introduction to Receptors; Signal Transduction; Antiviral Therapy; Pharmacology of Peptic Ulcers; Pharmacology of Insulin and Hypoglycemics
1988 - 1996	University of Pittsburgh, Department of Pharmacology. Second year Medical School Pharmacology course conferences
1981	Purdue University, Department of Biochemistry, laboratory teaching
1979	Washington State University, Department of Chemistry, laboratory teaching

**POSTDOCTORAL TRAINEES/RESEARCH ASSOCIATES**

1988 - 1992	Jetish Jani, Ph.D.	1998 - 2001	Frederic Delarue, Ph.D
1992 - 1993	Meenakshi Nigam, Ph.D.		
1992 - 1993	Churl M. Seong, Ph.D.	1997 - 2001	Jalila Adnane, Ph.D.
1991 - 1993	Thierry Camels, Ph.D.	1994 - 2003	Jiazhi Sun, M.D.
1993 - 1994	Steven Wathen, Ph.D.	2002- Present	Kun Jiang, Ph.D.
1994 - 1995	Elizabeth Tan-Chiu, M.D.	2002 - Present	James Hawker, Ph.D.
1994 - 1996	Zendong Pei, Ph.D.	2002 - Present	De-an Wang, Ph.D.
1992 - 1996	Terence McGuire, Ph.D.	2002 - Present	Kuichun Zhu, Ph.D.
1994 - 1996	Andreas Vogt, Ph.D.	2003- Present	Iian Duffy, Ph.D.
1995 - 1996	Jinan Yu, Ph.D.	2003-Present	Aslmuzaman Kazi, Ph.D.
1996 - 1998	P. K. Burnette, Ph.D.		
1995 - 2000	Jonathan Finder, M.D.		

**GRADUATE STUDENTS**

1992 - 1994	Renae Fossum (Co-adviser)
1992 - 1996	Yimin Qian (Co-adviser)
1993 - 1997	Edwina Lerner (Adviser)
1993 - 1998	William Stark (Co-adviser)
1996 - 1998	Pei Zhang (Adviser)
1996 - 2001	Zhi Chen (Adviser)
1997 - 2001	Nichole Crespo (Adviser)
2001 - 2002	Patrick Coppock (Adviser)
1997 - 2002	Cuider Allal (Co-adviser)
2003 - Present	Adam Carie
2003 - Present	Sam Falsetti

**UNDERGRADUATE:**

2002	Adam Carie
2001	Brian Busciglio
2001	Cassandra Martin
1998	Mary Brewer
1997	Brad Stigleman
1998	Janice Weatherspoon

**GRADUATE STUDENT COMMITTEES**

1989 - 1995	Kari Hoyt
1989 - 1994	Herng-Der Chern
1992 - 1994	Atsuhide Mori
1992 - 1995	Ming Huang
1992 - 1995	Robert Dixon
1993 - 1997	Diane M. Zeleski
1996 - 1998	Enfei He
2000 - 2004	Sophie Bolick
2000 - 2004	Michael Lee
2002 - Present	Amita Quadros

**UNDERGRADUATE STUDENTS  
HONORS THESIS:**

2000-2001	Adrian Kenny
2000-2001	Hong Chen
2002-2003	Cassandra Martin

**MENTORING PHYSICIAN SCIENTISTS**

1995 - 2000	Jonathan Finder, M.D.
2002 - Present	Stacy Moulder, M.D.
2002- Present	Mokenge Malafa, M.D.
2002 - Present	George Simon, M.D.



**RESEARCH****Grants Received (Over \$16,500,000 direct costs received since 1989):****Grant applications submitted:**

National Institutes of Health, NCDDG, “Inhibitors of Rho Function as novel cancer therapeutics”, May 1, 2005 – April 30, 2010, 20% effort, \$4,755,921 (Principal Investigator: S. M. Sebti)

National Institutes of Health, NCDDG, “Targeting Signal Transduction for Drug Discovery”, May 1, 2005 – April 30, 2010, 20% effort, \$4,436,257 (Principal Investigator: S. M. Sebti)

National Institutes of Health, R01 CA106829-01, “Growth Factor Binding Molecules as Anti-angiogenesis and Anti-oncogenesis Agents”, December 1, 2004 – November 30, 2009, 20% effort, \$1,562,566, (Principal Investigator: S.M. Sebti)

**Grants received:**

National Institutes of Health, RO1, “Targeted Intervention of Breast Oncogenic Pathways”, June 13, 2003 – May 31, 2008, 15% effort, \$1,001,250 (Principal Investigator: S.M. Sebti)

National Institutes of Health, CA99-010 National Cooperative Drug Discovery Groups, “Geranylgeranyltransferase I Inhibition and Cancer Therapy”, September 1, 2000 to April 30, 2005, 20% effort, \$3,293,527 (Principal Investigator: S.M. Sebti)

National Institutes of Health RO1 CA 85709-01, “AKT2 survival pathways and FTI-induced apoptosis”; January 18, 2001 to December 31, 2005; 15% effort, \$634,000, (Principal Investigator: S. M. Sebti)

National Institutes of Health RO1 CA83978-01, “Farnesyltransferase Inhibitors in Cancer Therapy: Bench to Bedside”, May 1, 2000 to April 30, 2005; 15% effort, \$675,000 (Principal Investigator: S.M. Sebti).

National Institutes of Health, RO1 CA94851, “Pharmacological rescue of mutant p53 function”, 01/01/03 – 01/01/08, 5% effort, \$1,000,000 (Co-Principal Investigator: S. M. Sebti)

National Institutes of Health PO1, CA78038-01A1, “Cancer Drug Discovery: Cell Cycle Control Targets”; September 1, 1999 – February 29, 2004; 20% effort, \$3,170,281, (Principal Investigator: S.M. Sebti)

AstraZeneca UK Ltd., “Evaluation of AZD3409 as a Dual Inhibitor of Farnesyl and Geranylgeranyl”, September 30, 2003 – October 1, 2004, \$250,000 (Principal Investigator: S.M. Sebti).

Medicines for Malaria Venture, Sub-contract to Yale University, February 22, 2002 – February 21, 2004, \$104,718

National Institutes of Health, “Development of Farnesyltransferase Inhibitor Therapy for Myelodysplasia”; April 1, 2001 to May 31, 2003; 5% effort, \$220,400 (Co-Principal Investigator: S. M. Sebti)

National Institutes of Health NCDDG, U19-CA67771 “Ras Farnesylation Inhibitors: Rational Cancer Drug Design”; September 1, 1995 - August 31, 2000; \$2,563,985, 30% effort (Principal Investigator: S.M. Sebti)

National Institutes of Health, Supplement to CCSG, P30 CA 76292-02, “FTI phase II trials: Correlative laboratory studies”, August 1, 1999 to July 31, 2002, \$92,200 (Co-Principal Investigator: S. M. Sebti).

National Institutes of Health, CA423146, "Expression levels of small G-proteins in the NCI 60 cell lines". January 1, 1998 – August 31, 2000; \$70,978, (Principal Investigator: S.M. Sebti).

Abbott Laboratories, Sponsored Research Agreement. "Prenylation inhibitors"; Jan. 1996 – Jan. 1999; \$1,127,700, 20% effort (Principal Investigator: S.M. Sebti)

National Institutes of Health, Chemoprevention Branch, Subcontract from Medical College of Ohio, September 1997 – September 1999, \$50,000 (Principal Investigator: S.M. Sebti).

National Institutes of Health KO8 "Ras CAAX Peptidomimetics in Pulmonary Inflammation"; July 1, 1996 – June 31, 2001; \$412,020, (Recipient: Jonathan D. FINDER, Mentor: Saïd M. Sebti, Ph.D.)

NATO Conference Workshop "Protein-Protein and Protein-Lipid Interactions in Signal Transduction: Use of Small Synthetic Molecules as Probes and Therapeutic Agents; 1997; \$50,000, (Workshop Director: S.M. Sebti).

National Institutes of Health ROI CA-48905 "Bleomycin Hydrolase and Tumor Resistance to Bleomycin"; Jan. 1, 1993 – Jan. 1, 1997; \$715,890, 30% effort (Principal Investigator: S.M. Sebti)

National Institutes of Health SBIR 94-3 "Developing Technologies for Studying Protein Prenylation"; October 1, 1995 – April 1, 1996; \$99,950, 15% effort (Principal Investigator: E. Schaefer)

National Institutes of Health ROI CA-55823 "Ras Oncogene p21 Farnesyl Transferase: A Novel Anticancer Target"; May 1, 1992 – May 1, 1995; \$504,900, 30% effort (Principal Investigator: S.M. Sebti)

National Institutes of Health NCI ROI CA-48905 "Bleomycin Hydrolase and Tumor Resistance to Bleomycin" Jan. 1, 1990 – Jan. 1, 1993; \$469,980, 30% effort (Principal Investigator: S.M. Sebti)

American Cancer Society "Membrane Association of Ras Oncoprotein as a Novel Anticancer Therapy Target"; Jan. 1, 1992 – April 30, 1992; \$46,200, 30% effort (Principal Investigator: S.M. Sebti)

National Institutes of Health "Involvement of Bleomycin Metabolism in Tumor Resistance to Bleomycin" Sept. 1, 1990 – Sept. 1, 1992; \$66,000 (J.P. Jani, Postdoctoral Fellow)

American Cancer Society JFRA-248 "Mechanism of Tumor Resistance to Bleomycin", Jan. 1, 1989 – Jan. 1, 1992; \$85,500 (Junior Faculty Research Award: S.M. Sebti)

American Cancer Society IN-58Z "Expression of Bleomycin Hydrolase in Bleomycin-Resistant and –sensitive Human Tumor Cells" Feb. 1, 1988 – July 1, 1988, \$5000 (Principal Investigator: S.M. Sebti)

University of Pittsburgh "Molecular Cloning and Expression of Bleomycin Hydrolase cDNA" July 1, 1988 – July 1, 1989; \$8000 (Principal Investigator: S.M. Sebti)

## INVITED SEMINARS

**1984**

Medical College of Ohio, Department of Pathology, Toledo, OH.  
Yale University, School of Medicine, Department of Pharmacology, New Haven, CT.

**1986**

International Minerals and Chemicals, Terre Haute, IN.  
Pharmacia, Piscataway, NJ.

**1987**

Mobil Corporation, Princeton, NJ.

**1988**

Duquesne University, Department of Chemistry, Pittsburgh, PA.

**1989**

Fox Chase Cancer Center, Philadelphia, PA.  
Pittsburgh Cancer Institute, Pittsburgh, PA.

**1990**

Developmental Therapeutics Program. University of Pittsburgh, PA.

**1991**

Pittsburgh Cancer Institute, Annual Retreat, Oglebay, PA.

**1992**

Center for Clinical Pharmacology, University of Pittsburgh, PA.  
Immunology Research in Progress, University of Pittsburgh, PA.  
Discussion Leader at the Pittsburgh Cancer Institute Research Scientific Retreat, Neamacolin Woodlands, PA.  
Tampa Bay Research Institute, Clearwater, FL.

**1993**

University of Tennessee, School of Medicine, Department of Pharmacology, Memphis, TN.  
The Chicago Medical School, Department of Molecular Pharmacology, Chicago, IL.  
University of Connecticut Health Center, Department of Pharmacology, Farmington, CT.  
Medical College of Ohio, Department of Pharmacology and Therapeutics, Toledo, OH.  
Saint Jukes Children's Research Hospital, Department of Pharmacology, Memphis, TN.  
Annual Virology Symposium on Oncogenes, Pittsburgh, PA.  
Hoffmann-LaRoche, Inc., Nutley, NJ.  
Castle Group, Inc., New York, NY.  
National Cancer Institute, Division of Cancer Treatment, Experimental Therapeutics Program, Rockville, MD.  
Schering-Plough Research Institute, Tumor Biology, Kenilworth, NJ.  
Pfizer, Inc., Cancer Biology Program, Groton, CT.  
Atlas Ventures, Boston, MA.

**1994**

Univ. of Pittsburgh, Department of Environmental and Occupational Health, Pittsburgh, PA.  
Oncologix, Gaithersburg, MD.  
Purdue University, Department of Medicinal Chemistry, West-Lafayette, IN.  
Promega Corp. Madison, WI.  
Biomeasure, Inc., Boston, MA.  
Pfizer, Inc., Cancer Biology Program, Groton, CT.  
Institut Pasteur, Centre National de Recherche Scientifique, Service d'Oncology Moleculaire, Lille,

France.

Institut Henri Beaufour, Paris, France.

Rhone-Poulenc Rorer, Pharmacologie Moleculaire Anticancer, Paris, France.

Miles Pharmaceuticals, Cancer Program, West Haven, CT.

Burroughs, Wellcome Co., Experimental Therapy Program, Research Triangle Park, NC

Annual Meeting of the American Association of Cancer Research, Speaker and Co-Chair

Minisymposium, Toronto, Canada

#### 1995

Eli Lilly and Co., Cancer Division, Indianapolis, IN

Abbott Laboratories, Oncology Division, Chicago, IL

Bayer Pharmaceuticals, Cancer Program, West Haven, CT

University of South Florida, H. Lee Moffitt Cancer Center, Tampa, FL.

University of Medicine and Dentistry of New Jersey, Molecular Biology Department, Stratford, NJ.

Cold Springs Harbor laboratory meeting. Neurofibromatosis: How to develop therapies. Cold Spring Harbor, NY.

Louisiana State University, Stanley Scott Cancer Center, New Orleans, Louisiana

Wayne State University, Department of Pharmacology, Detroit, MI.

#### 1996

Mayo Clinic, Cancer Center, Rochester, MN.

University of Vermont, School of Medicine, Dept. of Pharmacology, Burlington, VT.

Biochemical Society meeting, "Function and Pharmacology of protein Prenylation." Liverpool, England.

Zeneca Pharmaceuticals, Cancer, Metabolism & Endocrine Research Department, Manchester, England

Institut de Recherche Pierre Fabre, Division de Cancerologie, Castre, France

Centre Claudius Regaud, Oncologie Moleculaire, Toulouse, France.

University of Chicago, Hematology/Oncology, Chicago, IL.

Strategic Research Institute, "Signal Transduction and Disease", Symposium speaker, Philadelphia, PA.

#### 1997

Joint Cancer Conference of the FL Universities. Speaker, Orlando, FL

Fourth Drug Discovery and Development Symposium. Speaker, Annapolis, WA.

University of South Florida, Biochemistry and Molecular Biology, Tampa, FL.

American Society of Clinical Oncology 33<sup>rd</sup> Annual Meeting. Speaker at Pancreatic Cancer Session, Denver, CO.

University of South Florida, "Bench to Bedside" H. Lee Moffitt Cancer Center, Tampa, FL.

University of Pennsylvania, Department of Radiation Oncology, Pennsylvania, PA.

American Cancer Society Twentieth Annual Research Seminar. Keynote speaker, Orlando, FL.

Symposium on "Recent Advances in the Chemotherapy of Solid Tumors and Hematologic Malignancies", Speaker, Tampa, FL.

FASEB Meeting, Speaker, Snowmass, CO.

NATO Advanced Research Workshop on "Protein-Protein and Protein-Lipid Interactions in Signal Transduction: Use of Small Synthetic Molecules as Probes and Therapeutic Agents". Workshop director, co-organizer and speaker, Clearwater, FL.

Strategic Research Institute "Signal Transduction and Disease". Symposium Speaker, Philadelphia, PA

**1998**

Rotary Club, "Cancer Drug Discovery In Academia: An Invaluable Vehicle for Technology Transfer", Tampa, Florida

Yale University, Department of Pharmacology. Speaker, New Haven, Connecticut

NABTT Workshop, "Angiogenesis and Brain Tumor Therapy", Speaker, Tampa, FL

Annual Meeting of the American Association of Cancer Research, Speaker and Co-Chair Minisymposium, New Orleans, LA

H. Lee Moffitt Cancer Center Foundation Board of Directors, Speaker, Tampa, FL

Novalon Pharmaceuticals, Speaker, Raleigh, North Carolina

University of Pittsburgh, Dept. of Pharmacology, Speaker, Pittsburgh, Pennsylvania

H. Lee Moffitt Cancer Center, Grand Rounds Speaker, Tampa, Florida

NCI, Phase I Investigators Meeting, Gaithersburg, Washington, D.C., Speaker

5<sup>th</sup> International Union Against Cancer Workshop on Targeted Cancer Therapy, Speaker, Bermuda

**1999**

Miami Nature Biotechnology Symposium, "Inhibition of Protein Prenylation: A novel approach to cancer and cardiovascular disease therapy", Speaker, Miami, Florida

University of South Florida and H. Lee Moffitt Cancer Center Symposium "Non-small Cell Lung Cancer: Innovative Treatment Approaches", Speaker, Tampa, FL

Annual Meeting of the American Association of Cancer Research, Speaker and Co-Chair Minisymposium, Philadelphia, PA

Spring CTEP phase I Investigators Meeting at National Cancer Institute, Speaker, Bethesda, MD

6<sup>th</sup> International Association for the Study of Lung Cancer Lung Biology Workshop, Speaker, Aspen, Colorado

Fifth Drug Discovery and Development Symposium, Speaker, Detroit, Michigan

University of Central Florida, Speaker, Orlando, Florida

University of Florida Department of Biochemistry and Molecular Biology, Speaker, Gainesville, Florida

National Cancer Institute, DTP, Special Seminar Series, Speaker, Washington D.C.

**2000**

Monsanto, Searle Pharmaceutical, Discovery Oncology, St. Louis, MO

Regerone Pharmaceuticals, Inc., Tarrytown, NY

"Cultural Diversity in Clinical Research" sponsored by University of South Florida, speaker, Orlando, Florida

Lung Cancer State of Science meeting, National Cancer Institute, Washington D.C.

First International Lung Cancer Conference, Speaker, Maui, Hawaii

Post-International Association for the Study of Lung Cancer, Speaker, Chicago, Illinois

Annual Meeting of the American Association of Cancer Research, Speaker and Co-Chair Minisymposium, San Francisco, CA

New Molecular Targets in Cancer Therapy, Speaker and Co-organizer, St. Petersburg Bch, FL

First Annual Opinion Leader Roundtable "Targeted Therapies in the Treatment of Lung Cancer", Speaker, Aspen, CO

**2001**

MD Anderson Cancer Center, Department of Bioimmunotherapy, Guest Speaker, Houston, TX

Annual meeting of the American Association of Cancer Research, Speaker & Co-chair, Minisymposium on farnesyltransferase inhibitors, New Orleans, LA

Robert Lurie Comprehensive Cancer Center, Northwestern University, Speaker, Chicago, IL

Expert's Roundtable on Cell Signaling, sponsored by Dana-Farber Cancer Institute, Speaker, Banff, Alberta, Canada

NCI Workshop entitled, "Modeling human lung cancer in mice", Speaker, Boston, MA

Gordon Research Conference on Chemotherapy of Clinical and Experimental Cancer, Speaker, New London, NH

Tulane University, Speaker, New Orleans, LA

NCI/CTEP Signal Transduction Working Group Meeting, Washington DC

NCI CTEP Drug Development Meeting, Fall 2001 Phase I Meeting, Speaker, Bethesda, MD

Chair & Speaker, plenary session on "Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications", AACR-NCI-EORTC meeting, Miami, Florida

Salick Health Care Annual Research Group Meeting, Speaker, Miami, Florida

NCI Molecular Targets Retreat, speaker, Washington, D.C.

ZARNESTRA Hematologic Malignancies Roundtable, Speaker, Orlando, Florida

## **2002**

Joint Cancer Conference of Florida Universities, speaker, Orlando, Florida

Institute for Drug Development, Speaker, San Antonio, TX

Second Annual Opinion Leader Symposium, "Targeted Therapies in the Treatment of Lung Cancer", Speaker, Scottsdale, AZ

ILEX Oncology, Speaker, San Antonio, TX

Meet-the-Expert Sunrise Session, Annual meeting of American Association for Cancer Research, "Farnesyltransferase as a Target", speaker, San Francisco, CA

Memorial Sloan-Kettering Cancer Center, Speaker, New York, NY

Dartmouth College, Speaker, Hanover, NH

Annual Meeting of the American Society of Clinical Oncology, "Farnesyltransferase and Raf/MEK/Erk as Targets for Anticancer Drug Discovery", Speaker/Commentator, Orlando, FL

H. Lee Moffitt Cancer Center Research Retreat, "Inhibitors of Farnesyltransferase in Human Cancer", Speaker, Tampa, FL

1<sup>st</sup> International Congress on Targeted Therapies, Speaker, Washington DC

Oncology Fellows Connect 2002, Speaker, Rancho Mirage, CA

American Society of Hematology, Speaker, Philadelphia, PA

## **2003**

University of Pittsburgh, Department of Pharmacology, Speaker, Pittsburgh, PA

Targeted Therapies of Hematologic Malignancies, Speaker, Kona, Hawaii

Targeted Therapies for the Treatment of Breast Cancer, Speaker, Kona, Hawaii

Roswell Park Cancer Institute, Invited Speaker

## **2004**

University of Texas Southwestern, Invited Speaker

3<sup>rd</sup> International Congress on Targeted Therapies in Cancer, Washington DC, Invited Speaker

The Future of Lung Cancer: A Translational Focus, Las Vegas, Nevada, Invited Speaker

### SESSION CHAIRMANSHIPS

- 1995 American Association for Cancer Research Annual Meeting. Chairperson of Mini Symposium on "Targeting Ras", Toronto, Canada
- 1998 American Association for Cancer Research Annual Meeting, Chairperson, mini-symposium - Farnesyltransferase, New Orleans, Louisiana
- 1999 American Association for Cancer Research Annual Meeting, Chairperson Poster Discussion on "Farnesyltransferase Inhibitors", Philadelphia, PA
- 2000 Moffitt Research Retreat, Chairperson, Renal and Prostate Cancer, Tampa, FL
- 2000 American Association for Cancer Research Annual Meeting, Chairperson, mini-symposium - "Farnesyltransferase Inhibitors", San Francisco, CA
- 2001 American Association for Cancer Research Annual Meeting, Chairperson, mini-symposium - "Farnesyltransferase Inhibitors", New Orleans, LA
- 2001 Chair & Speaker, plenary session on "Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications", AACR-NCI-EORTC meeting, Miami, Florida
- 2002 Moffitt Research Retreat, Chairperson, Drug Discovery, Tampa, FL
- 2003 Moffitt Scientific Research Retreat, Chairperson, Drug Discovery, Tampa, FL

### OTHER RESEARCH RELATED ACTIVITIES

#### Editorial Board:

Cancer Biology and Therapy  
Molecular Cancer Therapeutics  
Investigational New Drugs

#### Reviewer for the following journals:

Biochemistry	Journal of Neurochemistry
Molecular Pharmacology	Journal of Cellular Biology
Cancer Research	Current Pharmaceutical Design
Oncology Research	Journal of Experimental Research
Biochemical Pharmacology	Oncogene
Biochimica et Biophysica Acta	Clinical Cancer Research
Journal of Medicinal Chemistry	Life Science

### UNIVERSITY SERVICE

Director, Library Committee - Department of Pharmacology, University of Pittsburgh, School of Medicine, 1987-1992.  
Member, Recruitment Committee - Department of Pharmacology, University of Pittsburgh, School of Medicine, 1987-1991.  
Director, Graduate Program - Department of Pharmacology, University of Pittsburgh, School of Medicine, 1988-1990.  
Chairman, Curriculum Planning and Administration Committee, Department of Pharmacology, Univ. of Pittsburgh, School of Medicine, 1990-1992.

Member, University of Pittsburgh Medical School Safety Committee, 1990-1995.  
Member, School of Medicine Curriculum Revision Committee, University of Pittsburgh, 1990-1993.  
Director, Graduate Program, Department of Pharmacology, University of Pittsburgh, School of Medicine, 1995-1996.  
Director, Drug Discovery Program, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, 1996 – Present  
Member, Recruitment Committee for Basic Sciences – H. Lee Moffitt Cancer Center & Research Institute, 1996 – Present.  
Member, Scientific Leadership Council, H. Lee Moffitt Cancer Center and Research Institute, 1996-Present.  
Member, Executive Council, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, 1996 – Present  
Chair, H. Lee Moffitt Cancer Center Foundation Scientists Campaign, 1998  
Member, Search Committee for Department of Chemistry Chair, University of South Florida, 1998  
Member, Microarray Advisory Board, H. Lee Moffitt Cancer Center & Research Institute, 1999 – present  
Member, Translational Core Committee, H. Lee Moffitt Cancer Center & Research Institute, 1999 – present  
Member, Technology Transfer Steering Committee, H. Lee Moffitt Cancer Center & Research Institute, 1999 – present  
Member, Appointment, Promotion & Tenure Committee, School of Medicine, University of South Florida, 2000 – Present  
Member, Institute for Biomolecular Science Redirection Committee, University of South Florida, 2001  
Member, Philanthropic Review Committee, H. Lee Moffitt Cancer Center, 2001  
Member, Search Committee for Director of Center for Entrepreneurship, University of South Florida, 2001  
Member, Scientific Advisory Committee, Moffitt Research Institute, 2002-present  
Member, Steering Committee for the Experimental Therapeutics Program, H. Lee Moffitt Cancer Center, 2002-present  
Member, Research Affiliation Process Committee, Moffitt Research Institute, 2002-Present  
Member, National Functional Genomics Steering Committee, Moffitt Cancer Center, 2002 - present  
Member, Search Committee for Associate Center Director for Clinical Investigations at Moffitt Cancer Center, 2003  
Member, Space Committee, Moffitt Cancer Center, 2003  
Member, Search Committee for Proteomics Core Director, H. Lee Moffitt Cancer Center & Research Institute, 2004  
Chair, Moffitt Research Institute Promotion and Tenure Policy committee, 2004  
Member, Proteomics Steering Committee, H. Lee Moffitt Cancer Center & Research Institute, 2004  
Member, High Throughput Steering Committee, H. Lee Moffitt Cancer Center & Research Institute, 2004  
Member, Task Force for Research Administration Support of Research, Moffitt Research Institute, 2004  
Member, Research IT/Bioinformatics Steering Committee, Moffitt Research Institute, 2004



## PATENTS

Lazo, J.S., Mistry, J.S., Jani, J.P. and Sebti, S.M. "Fluorescent-labeled bleomycin analogs". Filed 1990; Allowed, May, 1994; Serial No. 08/182,862, Issued May 30, 1995, Patent #5,420,228.

Sebti, S.M., Hamilton, A.D. and Seong, C.M. "Inhibition of Farnesyltransferase". Filed May 18, 1993; Allowed, May, 1995; Serial No. 08/062,287, Issued February 11, 1997, Patent #5,602,098.

Sebti, S.M. and Hamilton, A.D. "Inhibition of Farnesyltransferase" continuation-in-part. Filed January 12, 1995; allowed May 6, 1997; Serial No. 08/371,682. Issued January 6, 1998, Patent# 5,705,686.

Sebti, S.M. and Hamilton, A.D. "Inhibitors of Farnesyltransferase." Continuation-in-part. Filed May 30, 1995; Serial No. 08/451,839, Allowed April 21, 1998, Issued 11/10/98, Patent# 5,834,434.

Sebti, S.M. and Hamilton, A.D. "Inhibition of Farnesyltransferase." Divisional. Filed June 5, 1995. Serial No. 08/464,203, Allowed April 21, 1998, issued December 5, 1998, Patent# 5,856,310.

Palmer, J.W., Stanko, J.A., Burdge, J.R. and Sebti, S.M. "(Mono) Ethylenediaminenitroplatinum (IV) Complexes with Ligands of Oxides of Nitrogen as Possible Anti-Tumor Agents". Filed November 15, 1996. Serial No. 08/749,264, Issued December 15, 1998, Patent# 5,849,790.

Sebti, S.M. and Hamilton, A.D. "Inhibitors of Prenyltransferases." Omnibus. Filed January 11, 1996; Serial No. 08/584,654, Issued 10/12/99, Patent #5,965,539.

Sebti, S.M. and Hamilton, A.D. "Inhibition of Farnesyltransferase." Continuation-in-part. Filed January 2, 1996; Serial No. 08/582,076, Issued January 4, 2000, Patent #6,011,175.

Sebti, S.M. and McGuire, T. "Geranylgeraniol/Lovastatin: A Novel Approach to Blocking Cancer Transformation Without Cytotoxicity." Filed October 9, 1996; Serial No. 08/728,314, Issued July 4, 2000, Patent #6,083,979.

Sebti, S.M., Hamilton, A.D., Augeri, D.J., Barr, K.J., Donner, B.G., Fakhoury, S.A., Janowick, D.A., Kalvin, D.M., Larsen, J.J., Liu, G., O'Connor, S.J., Rosenberg, S.H., Shen, W., Swenson, R.E., Sorenson, B.K., Sullivan, G.M., Szczepankiewicz, B.G., Tasker, A.S., Wasicak, J.T., Winn, M. "Inhibitors of Protein Isoprenyl Transferases" Continuation-in-part. Filed May 7, 1997. Serial No. 08/852858, issued 12/17/99, Patent#98922122.1-2112.

McKenna, W.G., Muschel, R.J., Bernhard, E., Sebti, S.M. and Hamilton, A.D. "Sensitization of Cells to Radiation and Chemotherapy". Filed April 15, 1996; Application #60/015,477. WIPO: WO9738697, Publication date: October 23, 1997, Patent #714560.

Sebti, S.M., Hamilton, A.D., Barr, K.J., Fakhoury, S.A., O'Connor, S.J., Rosenberg, S.H., Shen, W., Sorenson, B.K., Sullivan, G.M., Wasicak, J.T., Henry, K.J. and Wang, L. "Inhibitors of Protein Isoprenyl Transferases" Continuation-in-part, Filed May 7, 1998. Serial No. 09/073,795, Issued April 24, 2001, Patent #6,221,865.

Sebti, S.M., Hamilton, A.D., Augeri, D.J., Barr, K.J., Donner, B.G., Fakhoury, S.A., Janowick, D.A., Kalvin, D.M., Larsen, J.J., Liu, G., O'Connor, S.J., Rosenberg, S.H., Shen, W., Swenson, R.E., Sorenson, B.K., Sullivan, G.M., Szczepankiewicz, B.G., Tasker, A.S., Wasicak, J.T., Winn, M. "Inhibitors of Protein Isoprenyl Transferases" Continuation-in-part, Filed May 7, 1998. Serial No. 09/073,807, issued March 20, 2001, Patent#6,204,293.

Sebti, S.M., Hamilton, A.D., Augeri, D.J., Barr, K.J., Donner, B.G., Fakhoury, S.A., Janowick, D.A., Kalvin, D.M., Larsen, J.J., Liu, G., O'Connor, S.J., Rosenberg, S.H., Shen, W., Swenson, R.E.,

Sorenson, B.K., Sullivan, G.M., Szczepankiewicz, B.G., Tasker, A.S., Wasicak, J.T., Winn, M. "Inhibitors of Protein Isoprenyl Transferases" Continuation-in-part, Filed May 7, 1998. Serial No. 09/073,818, issued October 30, 2001, Patent #6,310,095.

Sebti, S.M. and Hamilton, A.D. "Inhibition of Geranylgeranyltransferase." Filed November 3, 1995; Serial No. 08/552,554.

Sebti, S.M., Hamilton, A.D. and Rosenberg, S.H. "Inhibitors of Protein Isoprenyl Transferases" Provisional. Filed November 6, 1995; Serial No. 60/007,247.

Sebti, S.M. and Hamilton, A.D. "Inhibitors of Prenyltransferases." Filed January 11, 1996, PCT / US96 01559, International Publication #WO 96/21456, International publication date: July 18, 1996.

Sebti, S.M., Hamilton, A.D., Augeri, D.J., Barr, K.J., Donner, B.G., Fakhoury, S.A., Janowick, D.A., Kalvin, D.M., Larsen, J.J., Liu, G., O'Connor, S.J., Rosenberg, S.H., Shen, W., Swenson, R.E., Sorenson, B.K., Sullivan, G.M., Szczepankiewicz, B.G., Tasker, A.S., Wasicak, J.T., Winn, M. "Inhibitors of Protein Isoprenyl Transferases" Filed November 6, 1996; Serial No. 08/740,909.

Sebti, S.M., Hamilton, A.D., Augeri, D.J., Barr, K.J., Donner, B.G., Fakhoury, S.A., Janowick, D.A., Kalvin, D.M., Larsen, J.J., Liu, G., O'Connor, S.J., Rosenberg, S.H., Shen, W., Swenson, R.E., Sorenson, B.K., Sullivan, G.M., Szczepankiewicz, B.G., Tasker, A.S., Wasicak, J.T., Winn, M. "Inhibitors of Protein Isoprenyl Transferases" Continuation-in-part, Filed May 7, 1998. Serial No. 09/073,794.

Sebti, S.M., Adnane, J., Pledger, W.J., Jackson, R. "RAS/P21 transgenic mouse," Filed November 8<sup>th</sup> 2000, Issued March 11, 2003, 6,531,645.

Hamilton, A.D., Sebti, S.M., Peng, H. "Piperazinone Compounds as Anti-Tumor and Anti-Cancer Agents and Methods of Treatment", Filed January 22, 2004- European Patent Office. Serial No. 02796419 Issued April 26, 2004, Patent No: 6-2123-US0226881.

Jove, R., Dalton, W.S., Sebti, S.M. and Yu, H. "Inhibition of STAT3 Signal Transduction for Human Cancer Therapy", Filed January 27, 2000.

Sebti, S.M. and Hamilton, A.D. "Growth Factor-binding Molecules", filed March 21, 2001, PCT/US01/08920.

Sebti, S.M. "RhoB as a Suppressor of Cancer Cell Growth and Cell Transformation", Provisional Filed September 25, 2003.

Sebti, S.M. and Jove, R. "Inhibitors of STAT3 Activation", Provisional patent filed March 28, 2001.

Jimenez, S., Rosenbloom, J., Sebti, S., Hamilton, A. and Abrams, W. "Inhibition of Type 1 Collagen Expression in Normal and Systemic Sclerosis Fibroblasts by a Specific Inhibitor of Geranylgeranyltransferase I", Provisional patent filed June 25, 2001.

Sebti, S.M. and Jove, R. "Materials and Methods for Treatment of Cancer and Identification of Anti-cancer Compounds", Filed September 14, 2003.

Pledger, W.J., Jackson, R.J., Adnane, J. and Sebti, S.M. "RAS p27 animal models and uses thereof", Filed September 14, 2003.

Turkson, J., Jove, Richard, Sebti, S.M., Hamilton, A.D. "Peptidomimetic Inhibitors of Stat Activity", Filed February 20, 2004.

Sebti, S.M., Hamilton, A.D., Jain, R. "Inhibiting Angiogenesis and Tumorigenesis by Synthetic Molecules that Blocks Binding of Both VEGF and PDGF to Their Receptors", To be Filed.

### PUBLICATIONS

1. Sebti, S.M., Baird, W.M., Knowles, B.B. and Diamond, L. Benzo(a)pyrene-DNA adduct formation in target cells in a cell-mediated mutation assay. **Carcinogenesis**, 3: 1317-1320, 1982.
2. Sebti, S.M., Baird, W.M., Knowles, B.B. and Diamond, L. Binding of benzo(a)- pyrene to the DNA of target cells in a cell-mediated mutation assay. IN: Polynuclear Aromatic Hydrocarbons: Formation, Metabolism and Measurement. Eds: Cooke, M. and Dennis, A.J., Battelle Press, pp. 1077-1086, 1983.
3. Sebti, S.M. and Baird, W.M. Rat liver homogenate (s-9)-mediated binding of benzo(a)pyrene to DNA in V79 cells, V79 cell nuclei and aqueous solution. **Mutat. Res.**, 125: 307-314, 1984.
4. Pruess-Schwartz, D., Sebti, S.M., Gilham, P.T. and Baird, W.M. Analysis of benzo(a)pyrene-DNA adducts formed in cells in culture by immobilized boronate chromatography. **Cancer Res.**, 44: 4104-4110, 1984.
5. Pruess-Schwartz, D., Sebti, S.M., Bruner, G., Gilham, P.T. and Baird, W.M. Separation of benzo(a)pyrene-DNA adducts formed in cells in culture by chromatography on cellulose containing immobilized dihydroxyboryl groups. IN: Polynuclear Aromatic Hydrocarbons: Mechanisms, Methods and Metabolism. Eds: Cooke, M. and Dennis, A.J., Battelle Press, pp. 1029-1044, 1984.
6. Sebti, S.M., Pruess-Schwartz, D. and Baird, W.M. Species- and length of exposure-dependent differences in the benzo(a)pyrene - DNA adducts formed in embryo cell cultures from mice, rats, and hamsters. **Cancer Res.**, 45: 1594-1600, 1985.
7. Sebti, S.M., Moynihan, C.G., Anderson, J.N. and Baird, W.M. Benzo(a)pyrene- DNA adduct formation in target and activator cells in a Wistar rat embryo cell-mediated V79 cell mutation assay. **Carcinogenesis**, 6: 983-988, 1985.
8. Sebti, S.M., Smolarek, T.A., Salmon, C.P. and Baird, W.M. 7,12-dimethylbenz(a)anthracene: DNA adduct formation in Wistar rat and Syrian hamster embryo cell cultures. **Chemico-biological Interactions**, 56: 1-12, 1985.
9. Sebti, S.M., Moynihan, C.G., Pruess-Schwartz, P., Anderson, J.N. and Baird, W.M. Benzo(a)pyrene - DNA adduct formation in V79 target cells in a Wistar rat embryo cell-mediated mutation assay. IN: Polynuclear Aromatic Hydrocarbons. Eds: Cooke, M. and Dennis, A.J., Battelle Press, pp. 827-838, 1986.

10. Baird, W.M., Sebti, S.M. and Reinsvold, L.A. Metabolic activation of benzo(a)pyrene in Sencar and Balb/c mouse embryo cell cultures. **Environ. Health Perspect.**, 68: 45-52, 1986.
11. Lazo, J.S., Sebti, S.M. and Filderman, A.E. Metabolism of bleomycin and bleomycin-like compounds. IN: The Metabolism and Action of Anticancer Drugs. Eds: Prough, R.A. and Powis, G., Taylor and Francis, Ltd., London, pp. 194-210, 1987.
12. Baird, W.M., Smolarek, T.A., Sebti, S.M. and Pruess-Schwartz, D. Species differences in the metabolic activation of polycyclic aromatic hydrocarbons in cells in culture. IN: Chemical Carcinogenesis: Models and Mechanisms. Eds: Feo, F., Pani, P., Columbano, A. and Garcea, R., Plenum Press, 1987.
13. Sebti, S.M. and Lazo, J.S. Separation of the protective enzyme bleomycin hydrolase from rabbit pulmonary aminopeptidases. **Biochemistry**, 26: 432-437, 1987.
14. Sebti, S.M., DeLeon, J.C. and Lazo, J.S. Purification, characterization and amino acid composition of rabbit pulmonary bleomycin hydrolase. **Biochemistry**, 26: 4213-4219, 1987.
15. Sebti, S.M. and Lazo, J.S. Metabolic inactivation of bleomycin analogs by bleomycin hydrolase. **Pharmacol. Ther.**, 38: 321-329, 1988.
16. Lazo, J.S., Mignano, J.E. and Sebti, S.M. Pulmonary metabolic inactivation of bleomycin and protection from drug-induced lung injury. IN: Organ Directed Toxicities of Anticancer Drugs. Eds: Hacker, M. and Tritton, T.R., Martinus Nijhoff, Boston, pp. 128-139, 1988.
17. Lazo, J.S. and Sebti, S.M. Malignant cell resistance to bleomycin-group antibiotics. IN: Anticancer Drug Resistance. Ed: Kessel, D., CRC Press, pp. 267-279, 1989.
18. Sebti, S.M., DeLeon, J.C., Ma, L.-T, Hecht, S.M. and Lazo, J.S. Substrate specificity of bleomycin hydrolase. **Biochem. Pharmacol.**, 38: 141-147, 1989.
19. Sebti, S.M., Mignano, J.E., Jani, J.P., Srimatkandada, S., and Lazo, J.S. Bleomycin hydrolase: molecular cloning, sequencing and biochemical studies reveal membership in the cysteine proteinase family. **Biochemistry**, 28: 6544-6548, 1989.
20. Mistry, J.S., Sebti, S.M. and Lazo, J.S. Separation of bleomycins and their deamino metabolites by fast peptide liquid chromatography. **J. Chromatogr.**, 514: 86-90, 1990.
21. Lazo, J.S., Hoyt, D., Sebti, S.M. and Pitt, B.R. Bleomycin: A pharmacological tool in the study of the pathogenesis of interstitial pulmonary fibrosis. **Pharmacol. Ther.**, 47: 347-358, 1990.
22. Lazo, J.S. and Sebti, S.M. Bleomycins. IN: Cancer Chemotherapy and Biological Response Modifiers, Annual 12. Ed: H.M. Pinedo, D.L. Longo and B.A. Chabner, Elsevier Science Publishers B.V. pp. 51-58, 1991.
23. Sebti, S.M., Jani, J.P., Mistry, J.S., Gorelik, E. and Lazo, J.S. Metabolic inactivation: A mechanism of human tumor resistance to bleomycin. **Cancer Res.**, 51: 227-232, 1991.

24. Morris, G., Mistry, J.S., Jani, J.P., Sebti, S.M. and Lazo, J.S. Cysteine proteinase inhibitors and bleomycin sensitive and resistant cells. **Biochem. Pharmacol.**, 41: 1559-1566, 1991.
25. Sebti, S.M., Tkalcevic, G.T. and Jani, J.P. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-*ras* oncogene transformed cells in nude mice. **Cancer Commun.**, 3: 141-147, 1991.
26. Mistry, J.S., Jani, J.P., Morris, G., Mujumdar, R.B., Reynolds, I.J., Sebti, S.M. and Lazo, J.S. Synthesis and evaluation of fluoromycin: a novel fluorescence-labeled derivative of talisomycin S<sub>10b</sub>. **Cancer Res.**, 52: 709-718, 1992.
27. Jani, J.P., Mistry, J.S., Morris, G., Lazo, J.S. and Sebti, S.M. *In vivo* circumvention of human colon carcinoma resistance to bleomycin. **Cancer Res.**, 52: 2931-2937, 1992.
28. Lazo, J.S., Mistry, J.S. and Sebti, S.M. Fluoromycin: a novel bleomycin analog. **J. Cellular Pharmacology**, 3: 47-50, 1992.
29. Morris, G., Mistry, J.S. and Jani, J.P., Mignano, J.E., Sebti, S.M., and Lazo, J.S. Neutralization of bleomycin hydrolase by an epitope-specific antibody. **Mol. Pharmacol.**, 42: 57-62, 1992.
30. Lazo, J.S. and Sebti, S.M. Bleomycins. IN: Cancer Chemotherapy and Biological Response Modifiers, Annual 13. Ed: H.M. Pinedo, D.L. Longo and B.A. Chabner, Elsevier Science Publishers B.V., pp. 53-58, 1992.
31. Lazo, J.S., Hoyt, D.G., Sebti, S.M. and Pitt, B.R. The use of bleomycin in model systems to study the pathogenesis of interstitial pulmonary fibrosis. IN: International Encyclopedia of Pharmacology and Therapeutics, Chapter 15. Ed.: Gram, T.E., Pergamon Press, Ltd. (Oxford), pp. 271-287, 1992.
32. Nigam, M., Seong, C.M., Qian, Y., Hamilton, A., and Sebti, S.M. Potent inhibition of human tumor p21 *ras* farnesyl transferase by A<sub>1</sub>A<sub>2</sub>-lacking CA<sub>1</sub>A<sub>2</sub>X peptidomimetics. **J. Biol. Chem.**, 268: 20695-20698, 1993.
33. McGuire, T., Corey, S. and Sebti, S.M. Lovastatin inhibits PDGF stimulation of phosphatidyl inositol 3-kinase activity as well as the association of the p85 subunit to tyrosine-phosphorylated PDGF receptor. **J. Biol. Chem.**, 268: 22227-22230, 1993.
34. Lazo, J.S. and Sebti S.M. Bleomycins. IN: Cancer Chemotherapy and Biological Response Modifiers, Annual 14. Ed: H.M. Pinedo, D.L. Longo and B.A. Chabner. Elsevier Science Publishers B.V. pp 38-44, 1993.
35. Lazo, J.S., Hoyt, D.G., Sebti, S.M. and Pitt, B.R. The use of Bleomycin in Model Systems to Study the Pathogenesis of Interstitial Pulmonary Fibrosis. IN: Metabolic Activation and Toxicity of Chemical Agents to Lung Tissue and Cells., Ed. T.E. Gram, Pergamon Press, NY, pp. 267-283, 1993.
36. Sebti, S.M. and Lazo, J.S. Bleomycin hydrolase and tumor resistance to bleomycin. IN: International Encyclopedia of Pharmacology and Therapeutics. Ed.: A.C. Sartorelli and G. Powis, Pergamon Press, Ltd. (Oxford) Chapter 9 pp. 387-396, 1994.

37. Weng, W., Reynolds, I.J., Jani, J.P., Michelle Blaskovich, Sebti, S.M., Davies, P. and Pitt, B.R. Desensitization of 5HT<sub>2</sub> receptor by protein kinase C activation in distal pulmonary vascular smooth muscle cells in culture: **Microcirculation**, 1: 129-135, 1994.
38. Jani, J.P., Tkalcevic, G.T. and Sebti, S.M. Lovastatin inhibits *in vivo* tumor growth of H-*ras* and c-*myc* but not v-*src* oncogene-transformed cells. **Cellular Pharmacology**, 1: 67-72, 1994.
39. Qian, Y., Blaskovich, M., Saleem, M., Wathen, S., Hamilton, A., Sebti, S.M. Design and Structural Requirements of potent peptidomimetic inhibitors of p21<sup>ras</sup> Farnesyl Transferase. **J. Biol. Chem.**, 269: 12410-12413, 1994.
40. McGuire, T., Xu, X.-Q, Corey, S., Romero, G. and Sebti, S.M. Lovastatin disrupts early events in insulin signaling: A potential mechanism of lovastatin's anti-mitogenic activity. **Biochem. Bioph. Res. Comm.**, 204: 399-406, 1994.
41. Qian, Y., Blaskovich, M.A., Seong, C-M., Vogt, A., Hamilton, A.D. and Sebti, S.M. Peptidomimetic Inhibitors of p21<sup>ras</sup> Farnesyltransferase: Hydrophobic functionalization leads to disruption of p21<sup>ras</sup> membrane association in whole cells. **Biorg. Med. Chem. Lett.**, 4: 2579-2584, 1994.
42. Lazo, J.S. and Sebti, S.M. Bleomycins. IN: Cancer Chemotherapy and Biological Response Modifiers, Annual 15. Eds. H.M. Pinedo, B.A. Chabner and D.L. Longo. Elsevier Science Publishers B.V. (Biochemical Division), pp. 44-50, 1994.
43. Hamilton, A.D. and Sebti, S.M. Inhibitors of Ras farnesyltransferase as novel anti tumor agents. **Drug News and Perspectives**, 8: 138-145, 1995.
44. Vogt, A., Qian, Y., Blaskovich, M., Fossum, R., Hamilton, A. and Sebti, S.M. A non-peptide mimetic of Ras CAAX: Selective inhibition of farnesyltransferase and Ras processing. **J. Biol. Chem.**, 270: 660-664, 1995.
45. Pei, Z., Calmels, T., Creutz, C.E. and Sebti, S.M. Yeast cysteine proteinase YCP1 gene induces bleomycin resistance in mammalian cells. **Mol. Pharmacol.**, 48: 676-681, 1995.
46. Vogt, A., Sun, J., Qian, Y., Hamilton, A. and Sebti, S.M. Burkitt lymphoma Daudi cells contain two distinct farnesyltransferases with different divalent cation requirements. **Biochemistry**, 34: 12398-12403, 1995.
47. McGuire, T., Qian, Y., Blaskovich, M.A., Fossum, R.D., Sun, J., Marlowe, T., Corey, S.J., Wathen, S.P., Vogt, A., Hamilton, A. and Sebti, S.M. CAAX peptidomimetic FTI-244 decreases platelet-derived growth factor receptor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase. **Biochem. Bioph. Res. Comm.**, 214: 295-303, 1995.
48. Kauffman, R., Qian, Y., Vogt, A., Sebti, S.M., Hamilton, A. D. and Carthew, R. Activated Drosophila Ras 1 is selectively suppressed by Isoprenyltransferase inhibitors. **Proc. Natl. Acad. Sci.**, 92: 10919-10923, 1995.

49. Lerner, E., Qian, Y., Blaskovich, S. M., Fossum, R., Vogt, A., Cox, A., Der, C., Hamilton, A.D. and Sebti, S.M. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras/Raf complexes. **J. Biol. Chem.**, 270: 26802-26806, 1995.
50. Sun, Z., Qian, Y., Hamilton, A.D. and Sebti, S.M. Ras CAAX peptidomimetic FTI-276 selectively blocks in nude mice the growth of a human lung carcinoma with a K-Ras mutation and a p53 deletion. **Cancer Res.**, 55: 4243-4247, 1995
51. Lerner, E., Qian, Y., Hamilton, A.D., and Sebti, S.M. Disruption of oncogenic K-Ras 4B processing and signaling by a potent Geranylgeranyltransferase I inhibitor. **J. Biol. Chem.**, 270: 26770-26773, 1995.
52. Lazo, J.S., Sebti, S.M. and Schellens, J.H.M. Bleomycin. IN: Cancer Chemotherapy and Biological Response Modifiers, Annual 16. Eds. H.M. Pinedo, D.L. Longo and B.A. Chabner. Elsevier Science Publishers B.V. (Biochemical Division), pp. 39-47, 1995.
53. Qian, Y., Vogt, A., Sebti, S.M. and Hamilton, A.D. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors. **J. Med. Chem.** 39:217-233, 1996.
54. Xu, X., McGuire, T., Blaskovich, M.A., Sebti, S.M. and Romero, G. Effects of Lovastatin on the stimulation of mitogen-activated protein (MAP) kinase by insulin in HIRcB fibroblasts. **Archives of Biochem. Biophys.**, 326: 233-237, 1996.
55. Bernhard, E.J., Kao, G., Cox, A.D. Sebti, S.M., Hamilton, A.D., Muschel, R.J., and McKenna, W.G. The farnesyltransferase inhibitor FTI-277 radiosensitizes Ras<sup>H</sup>-transformed rat embryo fibroblasts. **Cancer Res.**, 56: 1727-1730, 1996.
56. Sebti, S. M. and Hamilton, A. D. Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs. **Biochem. Soc. Trans.**, 24: 692-699, 1996.
57. Der, C.J., Cox, A.D., Sebti, S.M. and Hamilton, A.D., Farnesyltransferase Inhibitors: Anti-Ras drugs for cancer treatment? **Anti-Cancer Drugs**, 7: 165-172, 1996.
58. Pei, Z., and Sebti, S.M. Cys<sup>102</sup> and His<sup>398</sup> are required for bleomycin-inactivating activity but not for hexamerformation of yeast bleomycin hydrolase. **Biochemistry**, 35: 10751-56, 1996.
59. Vogt, A., Qian, Y., Hamilton, A.D., and Sebti, S.M. Protein geranylgeranylation not farnesylation, is required for the G<sub>1</sub> to S phase transition in mouse fibroblasts. **Oncogene**, 13: 1991-1999, 1996.
60. McGuire, T., Qian, Y., Hamilton, A.D., and Sebti, S.M. Platelet Derived Growth Factor Receptor Tyrosine Phosphorylation Requires Protein Geranylgeranylation and Not Farnesylation. **J. Biol. Chem.**, 271: 27402-27407, 1996.
61. Lazo, J.S., and Sebti, S.M. Bleomycin. IN: Cancer Chemotherapy and Biological Response Modifiers, Annual 17. Eds. H.M. Pinedo, D.L. Longo and B.A. Chabner. Elsevier Science Publishers B.V. (Biochemical Division), pp. 40-45, 1997.

62. McGuire, T., and Sebti, S.M. Geranylgeraniol and lovastatin: A novel approach to blocking oncogenic H-Ras processing and signaling while restoring protein geranylgeranylation and preventing cytotoxicity. **Oncogene**, 14: 305-312, 1997
63. Sebti, S.M. and Hamilton, A.D. Inhibition of Ras prenylation: A novel approach to cancer chemotherapy. **Pharmacol. Ther.**, 74: 103-114, 1997.
64. Lerner, E.C., Hamilton, A.D., and Sebti, S.M. Inhibition of Ras prenylation: A signaling target for novel anticancer drug design. **Anti-cancer Drug Des.**, 12: 229-238, 1997.
65. Finder, J.D., Litz, J.L., Blaskovich, M.A., McGuire, T.F., Qian, Y., Hamilton, A.D., Davies, P., and Sebti, S.M. Inhibition of protein geranylgeranylation causes a superinduction of nitric oxide synthase-2 by IL-1 $\beta$  in pulmonary artery smooth muscle cells. **J. Biol. Chem.**, 272: 13484-13488, 1997.
66. Clark, G.J., Kinch, M.S., Rogers-Graham, K., Sebti, S.M., Hamilton, A.D., and Der, C.J. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. **J. Biol. Chem.**, 272: 10609-10615, 1997.
67. Miguel, K., Pradines, A., McGuire, T.M., Hamilton, A.D., Sebti, S.M. and Favre, G. GGTI-298 induces G0/G1 block and apoptosis whereas FTI-277 causes G2/M enrichment in A549 cells. **Cancer Res.**, 57: 1846-1850, 1997.
68. Qian, Y., Sebti, S.M. and Hamilton, A.D. Peptidomimetic inhibitors of farnesyltransferase: an approach to new antitumor agents. **Advances in Amino Acid Memetics and Peptidomimetics**. 1:165-192, 1997.
69. Sebti, S.M. and Hamilton, A.D. Inhibitors of prenyltransferases. **Curr. Opin. Oncol.**, 9: 557-561, 1997.
70. Qian, Y., Sebti, S.M., and Hamilton, A.D. Farnesyltransferase as a target for anti-cancer drug design. **Biopolymers (Peptide Science)**, 43:25-41, 1997.
71. Lerner, E.C., Zhang, T.T., Knowles, D., Qian, Y., Hamilton, A.D. and Sebti, S.M. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. **Oncogene**, 15(11): 1283-1288, 1997.
72. Vogt, A., Sun, J., Qian, Y., Hamilton, A.D., and Sebti, S.M. The geranylgeranyltransferase I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21 WAF/CIP/SDII in a-p53 independent manner. **J. Biol. Chem.** 272: 27224-27229, 1997.
73. Sebti, S.M. and Hamilton, A.D. Anticancer Activity of Farnesyltransferase and Geranylgeranyltransferase I Inhibitors: Prospects for Drug Development. **Expert Opinion on Investigational Drugs**. 6: 1711-1714, 1997.



74. Bernhard, E., McKenna, W.G., Hamilton, A.D., Sebti, S.M., Qian, Y., Wu, J. and Muschel, R.J. Inhibiting Ras Prenylation Increases the Radiosensitivity of Human Tumor Cell Lines with Activating Mutations of Ras Oncogenes. **Cancer Res.** 58: 1754-1761, 1998.
75. Qian, Y., Vogt, A., Vasudevan, A., Sebti, S.M., and Hamilton, A.D. Selective Inhibition of Type I Geranylgeranyltransferase *in vitro* and in Whole Cells by CAAL Peptidomimetics. **Biorg. Med. Chem. Lett.** (6): 293-299, 1998.
76. Sebti, S.M. and Hamilton, A.D. New approaches to anti-cancer drug design based on the inhibition of farnesyltransferase. **Drug Discovery**, 3: 26-33, 1998.
77. Sun, J., Qian, Y. Hamilton, A.D., and Sebti, S.M. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. **Oncogene**, 16(11): 1467-1473, 1998.
78. Bredel, M., Pollack, I.F., Freund, J.M., Hamilton, A.D. and Sebti, S.M. Inhibition of Ras and Related G-Proteins as a Therapeutic Strategy for Blocking Malignant Glioma Growth. **Neurosurgery**, 43(1): 124 – 132, 1998.
79. Stark, W.W., Blaskovich, M.A., Johnson, B.A., Vasudevan, A., Hamilton, A.D., Sebti, S.M., and Davies, P. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in vascular smooth muscle cells. **Am. J. Physiol.** 275: L55-L63, 1998.
80. Adnane, J., Bizouarn, F., Qian, Y., Hamilton, A.D. and Sebti, S.M. p21WAF1/CIP1 is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a TGF $\beta$ /Sp1-responsive element: Involvement of the small GTPase RhoA. **Mol. Cell. Biol.** 18(12): 6962-6970, 1998.
81. Kucich, U., Rosenbloom, J.C., Shen, G., Abrams, W.R., Blaskovich, M.A., Ohkanda, J., Hamilton, A.D., Sebti, S.M. and Rosenbloom, J. Requirement for Geranylgeranyl Transferase I and Acyl Transferase In the TGF- $\beta$  Stimulated Pathway Leading to Elastin mRNA Stabilization. **Biochem. Biophys. Res. Commun.** 252(1): 111-116, 1998.
82. Sun, Z., Qian, Y., Chen, Z., Marfurt, J., Hamilton, A.D. and Sebti, S.M. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of Rb and partner switching of cyclin-dependent kinase inhibitors: A potential mechanism for GGTI-298 antitumor activity. **J. Biol. Chem.** 274: 6930-6934, 1999.
83. Vasudevan, A., Qian, Y., Vogt, A., Blaskovich, M., Sebti, S.M. and Hamilton, A.D. Potent, highly selective and non-thiol inhibitors of geranylgeranyltransferase I. **J. Med. Chem.** 42(8): 1333-40, 1999.
84. Cohen-Jonathan, E., Toulas, C., Ader, I., Monteil, S., Allal, C., Bonnet, J., Hamilton, A.D., Sebti, S.M., Daly-Schveitzer, N. and Favre, G. The Farnesyl Transferase Inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type Ras. **Radiat. Res.** 152: 404-411, 1999.

85. O'Connor, S.J., Barr, K.J., Wang, L., Sorensen B.K., Tasker, A.S., Sham, H., Ng, S.C., Cogen, J., Devine, E., Cherian, S., Saeed, B., Zhang, H., Lee, J.Y., Warner, R., Tahir, S., Kovar, P., Ewing, P., Alder, J., Mitten, M., Leal, J., Marsh, K., Bauch, J., Hoffman, D.J., Sebti, S.M. and Rosenberg, S.H. Second-Generation Peptidomimetic Inhibitors of Protein Farnesyltransferase Demonstrating Improved Cellular Potency and Significant in Vivo Efficacy. **J. Med. Chem.** 42: 3701-3710, 1999.
86. Sun, J., Blaskovich, M.A., Knowles, D., Qian, Y., Ohkanda, J., Bailey, R.D., Hamilton, A.D. and Sebti, S.M. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, taxol and gemcitabine. **Cancer Res.** 59: 4919-4926, 1999.
87. Bowman, T., Yu, H., Sebti, S.M., Dalton, W. and Jove, R. Signal Transducers and Activators of Transcription: Novel Targets for Anticancer Therapeutics. **Cancer Control** 6: 427-435, 1999.
88. Pollack, I.F., Bredel, M., Erff, M., Hamilton, A.D. and Sebti, S.M. Inhibition of Ras and Related guanosine triphosphate-dependent proteins as a Therapeutic Strategy for Blocking Malignant Glioma Growth: II--Preclinical Studies in a Nude Mouse Model. **Neurosurgery** 45: 1208-1214, 1999.
89. Mazet, J-L., Padieu, M., Osman, H., Maume, G., Mailliet, P., Dereu, N., Hamilton, A., Lavelle, F., Sebti, S. and Maume, B.F. Combination of a novel farnesyltransferase inhibitor RPR-130401 and geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G<sub>i</sub>-S transition in Ki-Ras-overexpressing and [V12] H-Ras transformed adrenocortical cells. **FEBS Lett.** 460: 235-240, 1999.
90. Turkson, J., Bowman, T., Adnane, J., Zhang, Y., Djeu, J., Sekharam, M., Frank, D.A., Holzman, L.B., Wu, J., Sebti, S.M. and Jove, R. Requirement for Ras/Rac1-mediated p38 and JNK Signaling for STAT3 transcriptional activity induced by the Src oncoprotein. **Mol. Cell. Biol.** 19: 4919-4926, 1999.
91. Liu, L., Moesner, P., Kovach, N.L., Bailey, R., Hamilton, A.D., Sebti, S.M. and Harlan, J.M. Integrin-Dependent Leukocyte Adhesion Involves Geranylgeranylated Protein. **J. Biol. Chem.** 274: 33334-33340, 1999.
92. Qian, Y., Marugan, J.J., Fossum, R.D., Vogt, A., Sebti, S.M. and Hamilton, A.D. Probing the hydrophobic pocket of farnesyltransferase: Aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors. **Bioorg.Med.Chem.** 7: 3011-3024, 1999.
93. Carloni, V., Pinzani, M., Giusti, S., Romanelli, R.G., Parola, M., Bellomo, G., Failli, P., Hamilton, A.D., Sebti, S.M., Laffi, G. and Gentilini, P. Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on ras in human hepatic stellate cells. **Hepatology** 31: 131-140, 2000.
94. Lantry, L.E., Zhang, Z., Yao, R., Crist, K.A., Wang, Y., Ohkanda, J., Hamilton A., Sebti, S., Lubet, R.A., and You, M. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. **Carcinogenesis.** 21: 113-116, 2000.

95. Jiang, K., Coppola, D., Crespo, N.C., Nicosia, S.V., Hamilton, A.D., Sebti, S.M. and Cheng, J.Q. Phosphatidylinositol 3-kinase/AKT2 Pathway as a Critical Target for Farnesyltransferase Inhibitor-induced Apoptosis. **Mol. Cell. Biol.** 20: 139-148, 2000.
96. Boota, A., Johnson, B.A., Lee, K., Blaskovich, M.A., Liu, S.X., Kagan, V.E., Hamilton, A.D., Pitt, B.R., Sebti, S.M., and Davies, P. Prenyltransferase inhibitors block superoxide production by pulmonary vascular smooth muscle. **Am. J. Physiol.: Lung Cell Mol. Physiol.** 278: L329-L334, 2000.
97. Kucich, U., Rosenbloom, J.C., Shen, G., Abrams, W.R., Hamilton, A.D., Sebti, S.M. and Rosenbloom J. TGF- $\beta$ 1 Stimulation of Fibronectin Transcription in Cultured Human Lung Fibroblasts Requires Active Geranylgeranyl Transferase I, Phosphatidylcholine-specific Phospholipase C, Protein Kinase C- $\delta$  and p38, but not erk1/erk2. **Arch. Biochem. Biophys.** 374: 313-324, 2000.
98. Chen, Z., Sun, J., Pradines, A., Favre, G., Adnane, J. and Sebti, S.M. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. **J. Biol. Chem.** 275: 17974-17978, 2000.
99. Rosenbloom, J., Saitta, B., Gaidarova, S., Sandorfi, N., Rosenbloom, J.C., Abrams, W.R., Hamilton, A.D., Sebti, S.M., Kucich, U. and Jimenez, S.A. Inhibition of Type I Collagen Gene Expression in Normal and Systemic Sclerosis Fibroblasts by a Specific Inhibitor of Geranylgeranyltransferase I. **Arthritis and Rheum.** 43: 1624-1632, 2000.
100. Sebti, S.M. and Hamilton, A.D. Inhibition of Rho GTPases using protein geranylgeranyltransferase I inhibitors in *Methods Enzymol.* Academic Press, Ed. W.E. Balch, Channing J. Der and Alan Hall, 325: 381-388, 2000.
101. Wei, S., Gilvary, D.L., Corliss, B.C., Sebti, S.M., Sun, J., A.D., Straus, Leibson, P.J., Trapani, J.A., Hamilton, A.D., Weber, M.J. and Djeu, J.Y. Direct tumor lysis by NK cells uses a Ras-independent mitogen-activated protein kinase signal pathway. **J. Immunol.** 165: 3811-3819, 2000.
102. Blaskovich, M.A., Lin, Q., Delarue, F.L., Sun, J., Park, H.S., Coppola, D., Hamilton, A.D. and Sebti, S.M. Design of GFB-111 a platelet-derived growth factor binding molecule with anti-angiogenic and anti-cancer activity against human tumors in mice. **Nature Biotechnology** 18: 1065-1070, 2000.
103. Sebti, S.M. and Hamilton, A.D. Farnesyltransferase and Geranylgeranyltransferase I Inhibitors as Novel Agents for Cancer and Cardiovascular Diseases. In *Farnesyltransferase Inhibitors in Cancer Therapy.* Humana Press Inc., Ed. S. M. Sebti and A.D. Hamilton, pp.197-219, 2000.
104. Coxon, F.P., Helfrich, M.H., Van't Hof, R., Sebti, S.M., Ralston, S.H., Hamilton, A.D. and Rogers, M.J. Protein geranylgeranylation is required for osteoclast formation, function and survival: inhibition by bisphosphonates and GGTI-298. **J. Bone Miner. Res.** 15: 1467-1476, 2000.

105. Cohen-Jonathan, E., Muschel, R.J., McKenna, W.G., Evans, S., Cerniglia, G., Mick, R., Kusewitt, D., Sebti, S.M., Hamilton, A.D., Oliff, A., Kohl, N., Gibbs, J.B. and Bernhard, E.J. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. **Radiat. Res.** 154: 125-132, 2000.
106. Allal, C., Favre, G., Couderc, B., Sandrine, S., Sixou, S., Hamilton, A.D., Sebti, S.M., Lajoie-Mazenc, I. and Pradines, A. RhoA prenylation is required for promotion of cell growth and transformation, organization, but not for induction of SRE transcription. **J. Biol. Chem.** 275: 31001-31008, 2000.
107. Adnane, J., Bizouarn, F.A., Chen, Z., Ohkanda, J., Hamilton, A.D., Munoz-Antonia, T. and Sebti, S.M. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta. **Oncogene** 19: 5525-5533, 2000.
108. Adnane, J., Jackson, R.J., Nicosia, S.V., Cantor, A.B., Pledger, W.J. and Sebti, S.M. Loss of p21<sup>WAF1/CIP1</sup> accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. **Oncogene** 19: 5338-5347, 2000.
109. Gelb, M.H., Buckner, F.S., Yokoyama, K., Ohkanda, J., Hamilton, A.D., Nguyen, L., Rossi-Bergmann, B., Stuart, K.D., Sebti, S.M. and Van Voorhis, W.C. Protein Prenylation in Trypanosomatids: A New Piggy-Back Medicinal Chemistry Target for the Development of Agents Against Tropical Diseases. In Farnesyltransferase Inhibitors in Cancer Therapy. Humana Press Inc., Ed. S. M. Sebti and A.D. Hamilton, pp.221-232, 2000.
110. Sebti, S.M. and Hamilton, A.D. Farnesyltransferase and Geranylgeranyltransferase I Inhibitors in Cancer Therapy: Important Mechanistic and Bench to Bedside Issues. **Expert Opinion on Investigational Drugs** 9: 2767 – 2782, 2000.
111. Dey, A., She, H., Kim, L., Buroch, A., Guris, D.L., Carlberg, K., Sebti, S.M., Woodley, D.T., Imamoto, A. and Li, W. Colony-stimulating Factor-1 receptor utilizes multiple signaling pathways to induce cyclin D2 expression. **Mol. Biol. Cell** 11: 3835 – 3848, 2000.
112. Bernhard, E., Muschel, R., Cohen-Jonathan, E., Favre, G., Hamilton, A.D., Sebti, S.M. and McKenna, W.G. Prenyltransferase Inhibitors as Radiosensitizers. In Farnesyltransferase Inhibitors in Cancer Therapy. Humana Press Inc., Ed. S. M. Sebti and A.D. Hamilton, pp.171-195, 2000.
113. Knowles, D., Sun, J., Rosenberg, S., Sebti, S.M. and Hamilton, A.D. Peptidomimetic-Based Inhibitors of Farnesyltransferase. In Farnesyltransferase Inhibitors in Cancer Therapy. Humana Press Inc., Ed. S. M. Sebti and A.D. Hamilton, pp.49-64, 2000.
114. Zhang, H., Wei, S., Sun, J., Coppola, D., Zhong, B., Wu, G.D., Goodwin, B., Sebti, S., Djeu, J.Y., and Blanck, G. Retinoblastoma protein activation of interleukin-8 expression inhibits tumor cell survival in nude mice. **Cell Growth Differ.** 11: 635-639, 2000.
115. Kothare, M.A., Ohkanda, J., Lockman, J.W., Qian, Y., Blaskovich, M.A., Sebti, S.M. and Hamilton, A.D. Development of a tripeptide mimetic strategy for the inhibition of protein farnesyltransferase. **Tetrahedron** 56: 9833-9841, 2000.

116. Sebti, S.M. and Hamilton, A.D. Farnesyltransferase and Geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies. **Oncogene** 19: 6584 – 6593, 2000.
117. Sebti, S.M. and Hamilton, A.D. Design of growth factor antagonists with antiangiogenic and antitumor properties. **Oncogene** 19: 6566 – 6573, 2000.
118. Sun, J., Nam, S., Lee, C.-S., Li, B., Coppola, D., Hamilton, A.D., Dou, Q.P. and Sebti, S.M. CEP1612, a dipeptidyl proteasome inhibitor, induces p21<sup>WAF1</sup> and p27<sup>KIP1</sup> expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. **Cancer Res.** 61: 1280 – 1284, 2001
119. Ohkanda, J., Lockman, J., Yokoyama, K., Gelb, M.H., Croft, S.L., Kendrick, H., Harrell, M.I., Feagin, J.E., Blaskovich, M.A., Sebti, S.M. and Hamilton, A.D. Peptidomimetic Inhibitors of Protein Farnesyltransferase show Potent Antimalarial Activity. **Bioorg. Med. Chem. Let.** 11: 761 – 764, 2001
120. Crespo, N., Ohkanda, J., Yen, T., Hamilton, A.D. and Sebti, S.M. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. **J. Biol. Chem.** 276: 16161 – 16167, 2001.
121. Teng, S., Sun, J., Irby, R., Hamilton, A.D., Sebti, S.M. and Yeatman, T. V-Src Transformation is Mediated Through Farnesylated Proteins. **J. Surg. Res.** 99: 343-6, 2001.
122. Finder, J.D., Petrus, J.L., Hamilton, A.D., Villavicencio, R.T., Pitt, B.R. and S.M. Sebti Signal transduction pathways of IL-1 $\beta$  mediated induction of iNOS in cultured rat pulmonary vascular smooth muscle cells. **Am. J. Physiol. Lung Cell. Mol. Physiol.** 281: L816-23, 2001.
123. Kucich, U., Rosenbloom, J.C., Herrick, D.J., Abrams, W.R., Hamilton, A.D., Sebti, S.M. and Rosenbloom, J. Signaling events required for TGF- $\beta$  stimulation of connective tissue growth factor expression by cultured human lung fibroblasts. **Arch. Biochem. Biophys.** 395: 103-12, 2001.
124. Delarue, F.L., Taylor, B. and Sebti, S.M. Ras and RhoA suppress whereas RhoB enhances cytokine-induced transcription of nitric oxide synthase-2 in human normal liver AKN-1 cells and lung cancer A-549 cells. **Oncogene** 20: 6531-7, 2001.
125. Turkson, J., Ryan, D., Kim, J.S., Zhang, Y., Chen, Z., Haura, E., Laudano, A., Sebti, S., Hamilton, A.D. and Jove, R. Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation and cell transformation. **J. Biol. Chem** 276: 45443-55, 2001.
126. Gelb, M.H., Buckner, F.S., Yokoyama, K., Ohkanda, J., Hamilton, A.D., Nguyen, L., Sebti, S.M. and Van Voorhis, W.C. Protein Prenylation in Trypanosomatids: A New Piggy-Back Medicinal Chemistry Target for the Development of Agents Against Tropical Diseases. **Drugs Against Parasitic Diseases (France)** 2001.

127. Ohkanda, J., Lockman, J.W., Kothare, M.A., Qian, Y., Blaskovich, M.A., Sebti, S.M. and Hamilton, A.D. Design and synthesis of potent nonpeptidic farnesyltransferase inhibitors based on a terphenyl scaffold. **J. Med. Chem.** 45: 177-188, 2002.
128. Arteaga, C.L., Khuri, F., Krystal, G. and Sebti, S.M. Overview of Rationale and Clinical Trials with Signal Transduction Inhibitors in Lung Cancer. **Semin Oncol** 29: 15-26, 2002.
129. Adnane, J., Seijo, E., Chen, Z., Bizouarn, F., Leal, M., Sebti, S.M. and Munoz-Antonia, T. RhoB, not RhoA, represses the transcription of the transforming growth factor beta type II receptor by a mechanism involving AP1. **J. Biol. Chem.** 277: 8500-7, 2002.
130. Li, X., Liu, L., Tupper, J., Bannerman, D.D., Winn, R.K., Sebti, S.M., Hamilton, A.D. and Harlan, J.M. Inhibition of protein geranylgeranylation and RhoA/RhoA-kinase pathway induces apoptosis in human endothelial cells. **J. Biol. Chem.** 277: 15309-15316, 2002.
131. Walters, C.E., Pryce, G., Hankey, D.J.R., Hamilton, A.D., Sebti, S.M., Baker, D., Greenwood, J. and Adamson, P. Inhibition of Rho GTPases with protein Prenyl Transferase Inhibitors Prevent Lymphocyte Recruitment to the CNS and Attenuate Clinical Signs of Disease in an Animal Model of Multiple Sclerosis. **J. Immunol.** 168: 4087-4094, 2002.
132. Ohkanda, J., Knowles, D.B., Blaskovich, M.A., Sebti, S.M. and Hamilton, A.D. Inhibitors of protein farnesyltransferase as novel anticancer agents. **Curr. Top. Med. Chem.** 2: 303-323, 2002.
133. Crespo, N.C., Delarue, F., Ohkanda, J., Carrico, D., Hamilton, A.D. and Sebti, S.M. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. **Cell Death Differ.** 9: 702-709, 2002.
134. Adnane, J., Muro-Cacho, C., Mathews, L., Sebti, S.M. and Munoz-Antonio, T. Suppression of RhoB Expression in Invasive Carcinoma from Head and Neck Cancer Patients. **Clin. Cancer Res.** 8: 2225-2232, 2002.
135. Burdelya, L., Catlett-Falcone, R., Levitzki, A., Cheng, F., Mora, L.B., Sotomayor, E., Coppola, D., Sun, J., Sebti, S., Dalton, W.S., Jove, R. and Yu, H. Combination Therapy with AG-490 and Interleukin 12 Achieves Greater Antitumor Effects than Either Agent Alone. **Mol. Cancer Therap.** 1: 893-899, 2002.
136. Sikic, B.I., Sebti, S.M. and Eckhardt, S.G. New Agents and New Targets in Cancer Treatment: a Report from the Integrated Session of the ASCO Annual Meeting, pp 175-178, 2002.
137. Allal, C., Pradines, A., Hamilton, A.D., Sebti, S.M. and Favre, G. Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298. **Cell Cycle** 1: 430-7, 2002.
138. Jackson, R.J., Adnane, J., Coppola, D., Cantor, A., Sebti, S.M. and Pledger, W.J. Loss of the Cell Cycle Inhibitors p21<sup>cip1</sup> and p27<sup>kip1</sup> enhances tumorigenesis in knockout mouse models. **Oncogene** 21: 8486-97, 2002.

139. Mazzocca, A., Giusti, S., Hamilton, A.D., Sebti, S.M., Pantaleo, P. and Carloni V. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines. **Mol. Pharmacol.** 63: 159-66, 2003.
140. Ohkanda, J., Blaskovich, M.A., Sebti, S.M. and Hamilton, A.D. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents. **Prog Cell Cycle Res** 5:211-217, 2003.
141. Bolick, S.C.E., Landowski, T.H., Boulware, D., Oshiro, M.M., Ohkanda, J., Hamilton, A.D., Sebti, S.M. and Dalton, W.S. The farnesyltransferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug resistant myeloma tumor cells. **Leukemia** 2: 451-7, 2003.
142. Doisneau-Sixou, S., Cestac, P., Chouini, S., Hamilton, A.D., Sebti, S.M., Poirot, M., Balaguer, P., Faye, J.-C. and Favre, G. Constrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells. **Endocrinology** 144(3): 989-998, 2003.
143. Blaskovich, M.A., Sun, J., Turkson, J., Jove, R. and Sebti, S.M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. **Cancer Research** 63(6):1270-9, 2003.
144. Peng, Y., Li, C., Chen, L., Sebti, S.M. and Chen, J. Rescue of mutant p53 transcription function by ellipticine. **Oncogene** 22: 4478-4487, 2003.
145. Bordier B.B., Ohkanda J., Liu, P., Lee S-Y., Salazar F.H., Marion P.L., Ohashi K, Meuse L., Kay M.A., Casey J.L., Sebti S.M., Hamilton A.D., Glenn J.S. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus (HDV). **J. Clin. Invest.** 112: 407-417, 2003.
146. Zhang Z, Wang Y, Lantry LE, Kastens E, Liu G, Hamilton AD, Sebti SM, Lubet RA, You M. Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant negative p53 and/or heterozygous deletion of *Ink4a/Arf*. **Oncogene** 22: 6257-65, 2003.
147. Forsberg M, Blomgran R, Lerm M, Sarndahl E, Sebti SM, Hamilton A, Stendahl O and Zheng L. Differential effects of invasion by and phagocytosis of *Salmonella typhimurium* on apoptosis in human macrophages-potential role of Rho GTPases and Akt. **J of Leukoc. Biol.** 74: 620-9, 2003.
148. Santucci, R., Mackley, P., Sebti, SM, Alsina, M. Farnesyl transferase inhibitors and their role in the treatment of multiple myeloma. **Cancer Control** 10: 384-387, 2003.
149. Sun, J., Ohkanda, J., Coppola, D., Yin, H., Kothare, M., Busciglio, B., Hamilton, A.D. and Sebti, S.M. Geranylgeranyltransferase Inhibitor, GGTI-2154, Induces Breast Carcinoma Apoptosis and Tumor Regression in Ras Transgenic Mice. **Cancer Res** 63: 8922-8929, 2003.
150. Sebti, SM. Blocked Pathways: FTIs Shut Down Oncogene Signals. **Oncologist** 8 Suppl 3: 30-8, 2003.

151. Buckner, F., Yokoyama, K., Lockman, J., Aikenhead, K., Ohkanda, J., Sadilek, M., Sebti, S., Van Voorhis, W., Hamilton A. and Gelb, M. A new class of sterol 14-demethylase inhibitors as anti-*trypanosoma cruzi* agents. **Proc Natl Acad Sci USA** 100: 15149-53, 2003.
152. Kurzrock, R., Kantarjian, H.M., Cortes, J.E., Singhanian, N., Thomas, D.A., Wilson, E. F., Wright, J., Freireich, E.J., Talpaz, M. and Sebti, S.M. Farnesyltransferase Inhibitor R115777 in Myelodysplastic Syndrome: Clinical and Biologic Activities in the phase I Setting. **Blood** 102: 4527-34, 2003.
153. Der, C. and Sebti S.M. Opinion: Searching for the Elusive Targets of Farnesyltransferase Inhibitors. **Nature Reviews Cancer** 3: 945-951, 2003.
154. Zhu, K., Hamilton, A.D. and Sebti, S.M. Farnesyltransferase inhibitors as anti-cancer agents: current status. **Curr Opin Investig Drugs** 4: 1428-35, 2003.
155. Dan, Han C., Jiang, K., Coppola, D., Hamilton, AD, Nicosia, Santo V., Sebti, SM, Cheng, JQ. Phosphatidylinositol-3-OH Kinase/Akt and Survivin Pathways as Critical Targets for Geranylgeranyltransferase I Inhibitors Induced Apoptosis. **Oncogene** 23: 706-15, 2004.
156. Ohkanda, J., Buckner, F.S., Lockman, J.W., Yokoyama, K., Carrico, D., Eastman, R., de Luca-Fradley, K., Davies, W., Croft, S.L., Van Voorhis, W.C., Gelb, M.H., Sebti, S.M. and Hamilton, A.D. Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as Anti-*trypanosoma brucei* agents. **J. Med. Chem.** 47: 432-45, 2004.
157. Jiang, K., Delarue, F.L. and Sebti, S.M. EGFR, ErbB2, and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation. **Oncogene** 23: 1136-45, 2004.
158. Alsina, M., Fonseca, R., Wilson, E.F., Belle, N., Gerbino, E., Price-Troska, T., Overton, R., Ahmann, G., Bruzek, L., Adjei, A., Kaufmann, S., Wright, J.J., Sullivan, D., Djulbegovic, B., Cantor, A.B., Greipp, P.R., Dalton, W.S. and Sebti, S.M. Farnesyltransferase Inhibitor FTI-R115777 is well tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. **Blood** 103: 3271-3277, 2004.
159. Mazieres, J., Antonia, T., Daste, G., Muro-Cacho, C., Berchery, D., Tillement, V., Pradines, A., Sebti, S.M. and Favre, G. Loss of RhoB expression in human lung cancer progression. **Clin Cancer Res** 10: 2742-50, 2004.
160. Sun, J, Blaskovich, MA, Jain, R, Delarue, F, Paris, D, Brem, S, Wotocezk-Obadia, M, Lin, Q., Coppola, D, Choi, K, Mullan, M, Hamilton, AD, and Sebti, SM. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. **Cancer Research** 64: 3586-92, 2004.
161. Turkson, J., Kim J.S., Zhang, S., Yuan, J., Huang, M., Glenn M., Haura E., Sebti, S.M., Hamilton, A.D., and Jove, R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. **Mol Cancer Ther** 3: 261-9, 2004.



162. Sebti, S.M. and Adjei, A.A. Farnesyltransferase Inhibitors. *Semin Oncol* 31: 28-39, 2004.
163. Jiang, K, Sun, J, Cheng J, Djeu JY, Wei S and Sebti, S.M. Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion and metastasis. **Mol. Cell. Biol.** 24: 5565-76, 2004.
164. Paris, D., Townsend, K., Quadros, A., Humphrey, J., Sun, J., Brem, S., Wotoczek-Obadia, M., DelleDonne, A., Patel, N., Obregon, D., Crescentini, R., Abdullah, L., Coppola, D., Rojiani, A., Crawford, F., Sebti, S. and Mullan, M. Inhibition of angiogenesis by A $\beta$  peptides. **Angiogenesis** 7: 75-85, 2004.
165. Yang, L., Dan, H.C., Sun, M., Liu, Q., Sun, X-M, Feldman, R. I., Hamilton, A.D., Polokoff, M., Nicosia, S.V., Herlyn, M., Sebti, S.M., Cheng, J.Q. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. **Cancer Res** 64: 4394-9, 2004.
166. Gasparetto, M., Gentry, T., Sebti, S.M., O'Bryan, E., Nimmanapalli, R., Blaskovich, M.A., Bhalla, K., Rizzieri, D., Haaland, P., Dunne, J. and Smith, C. Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening. **J Immunol Methods** 292: 59-71, 2004.
167. Epling-Burnette, P.K., Bai, F., Wei, S., Painter, J.S., Olashaw, N., Hamilton, A.D., Sebti, S.M., Djeu, J., Loughran, T. ERK couples chronic survival of NK cells to constitutively-activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). **Oncogene** (In Press).
168. Dasgupta, P., Sun, J., Wang, S., Fusaro, G., Betts, V., Padmanabhan, J., Sebti, S.M. and Chellappan, S.P. Disruption of the Rb-Raf-1 Interaction Inhibits Angiogenesis and Tumor Growth. **Molecular Cellular Biology** (In Press).
169. Woo, J.T., Nakagawa, H., Krecic, A.M., Nagai, K., Hamilton, A.D., Sebti, S.M. and Stern, P.H. Inhibitory effects of Mevastatin and a geranylgeranyltransferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF $\kappa$ B ligand (RANKL) or tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ). **Biochemical Pharmacology** (In Press).
170. Carrico, D., Ohkanda, J., Kendrick, H., Yokoyama, K., Buckner, F.S., Van Voorhis, W.C., Croft, S.L., Gelb, M.H., Sebti, S.M. and Hamilton, A.D. In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. **Bioorganic & Medicinal Chemistry** (In Press).
171. Turkson, J., Zhang, S., Palmer, J., Kay, H., Stanko, J., Mora, L., Sebti, S., Yu, H. and Jove, R. Inhibition of constitutive Stat3 activation by novel platinum complexes with potent anti-tumor activity. **Molecular Cancer Therapeutics** (In Press).
172. Chen, L., Yin, H., Farooqi, B., Sebti, S., Hamilton, A.D., and Chen, J. Synthetic inhibitors based on terphenyl scaffold antagonize p53/mem2 interaction and activate p53. **Cancer Research** (Submitted)

173. Fefedova, Y., Gilkes, D., Cheng, P., Rosenbauer, A., Nagaraj, S., Blaskovich, M., Beg, A.A., Sebti, S.M. and Gabrilovich, D.I. Regulation of dendritic cell differentiation and activation in cancer by pharmacological selective inhibition of the Jak2/STAT3 pathway. **J. Clin Invest** (Submitted).
174. Yin, H., Lee, G-I, Payne, G.A., Rodriguez, J.M., Sebti, S.M. and Hamilton, A.D. Terphenyl-based helical mimetics that disrupt the p53/hdm2 interaction. (Submitted)
175. Carrico, D., Blaskovich, M.A., Bucher, C., Sebti, S.M. and Hamilton, A.D. Design, synthesis and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase I. **Bioorg. Med Chem** (Submitted).
176. Wang, D. and Sebti, S.M. Palmitoylated cysteine 192 is required for RhoB tumor suppressive and apoptotic activities. **J. Biol. Chem.** (Submitted).
177. Mazieres, J., Allal, C., Tillement, V., Bobin, L., Chen, Z., Sebti, S.M., Favre, G. and Pradines, A. Farnesylated RhoB enhances whereas geranylgeranylated RhoB suppresses Ras transformation in NIH-3T3 cells. **Cancer Research** (Submitted)
178. Nallan, L., Bauer, K., Bendale, P., Rivas, K., Yokoyama, K., Pendyala, P.R., Floyd, D., Lombardo, L., Williams, D.K., Hamilton, A., Sebti, S., Windsor, W.T., Weber, P., Buckner, F.S., Chakrabarty, D., Gelb, M.H. and Van Voorhis, W.C. Protein farnesyltransferase inhibitors exhibit potent anti-malarial activity. **Nature Medicine** (Submitted).
179. Delarue, F. L., Adnane, J., Bizouarn, F., Ohkanda, J., Hamilton, A.D. and Sebti, S.M. The GTPase RhoB, not RhoA, is transcriptionally induced by farnesyltransferase and geranylgeranyltransferase I inhibitors: Induction of RhoB does not correlate with human cancer cell growth inhibition. **Oncogene** (Submitted).
180. Peng, H., Carrico, D., Thai, V., Blaskovich, M., Bucher, C., Sebti, S.M. and Hamilton, A.D. Synthesis and Evaluation of Potent, Highly-selective, 3-Aryl-peperazinone Inhibitors of Protein Geranylgeranyltransferase I. **J. Med. Chem.** (Submitted).
181. Chen, Z., Komatsu, K., Wang, H-G and Sebti, S.M. RhoB binds RhoGDI-2, not RhoGDI-1, and inhibits its ability to promote colony formation in human pancreatic cells. **Biochemistry**(Submitted).
182. Ohkanda, J., Strickland, C.L., Blaskovich, M.A., Carrico, D., Lockman, J.W., Sun, J., Qian, Y., Knowles, D., Sebti, S.M. and Hamilton, A.D. Structure-based design and synthesis of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase. **J. Med. Chem.** (Submitted)
183. Cornejo, C.J., Liu, L., Hamilton, A.D., Sebti, S.M., Harlan, J.M. and Winn, R.K. Inhibition of protein prenylation blocks pulmonary inflammation and cytokine production in the mouse. (Submitted)
184. Stark, W.W., Hamilton, A.D., Sebti, S.M. and Davies, P. Inhibition of Protein Prenylation: A novel Approach to Blocking Small G-Protein in Smooth Muscle. (Submitted).

185. Tang, D., Park, H., Sebti, S. M., Hamilton, A. D., Galper, J. Statins Potentiate TNF $\alpha$  Mediated Apoptosis in Endothelial Cells: Role of Increased Expression of TNF $\alpha$  Receptor I. (Submitted).
186. Blaskovich, M., Sun, Z., Stanko, J., Palmer, J. and Sebti, S.M. Nitric oxide donor and platinum derivative, CPA-1, demonstrates potent antitumor activity against human lung carcinoma in a nude mouse model. **Nitro Oxide: Biology and Chemistry**. (Submitted).
187. Stark, W.W., Qian, Y., Hamilton, A.D., Sebti, S.M. and Davies, P. Rho proteins regulate cell growth and protect against apoptosis in pulmonary vascular smooth muscle cells. **J. Cell. Physiol.** (Submitted).
188. Shears, L., Sun, Z., Qian, Y., Billiard, T., Hamilton, A.D. and Sebti, S.M. Prenyltransferase inhibitors suppress neointima formation following rat artery angioplasty: geranylgeranyltransferase I inhibitors are more effective than farnesyltransferase inhibitors. **J. Mol. Cell. Cardiol.** (Submitted).
189. Epling-Burnette, P.K., Bai, F, Wei, S, Hamilton A., Painter, J.S., Sebti, S.M., Djeu, J.Y., Loughran, T.P. Constitutively active ERK controls chronic survival in NK type of lymphoproliferative disease of granular lymphocytes (LDGL). **J. Clin. Invest.** (Submitted).
190. Cloughesy, T., Paquette, S., Sebti S. A Phase I Trial of R115777 in Patients With Recurring Malignant Glioma Taking Enzyme-inducing Antiepileptic Drugs (EIAEDs): A North American Brain Tumor Consortium Study. **Journal of Clinical Oncology**. (Submitted)
191. Zuckerbraun, B.S., Barbato, J.E., Hamilton, A., Billiar, T.R., Sebti, S. and Tzeng, E. Geranylgeranyltransferase inhibition decreases generation of vascular reactive oxygen species and increases vascular nitric oxide production. **Circulation Research** (Submitted).
192. Sun, J.; Wang, De-An; Jain, R.; Paquette, S.; Ennis, Eileen; Blaskovich, Michelle; Baldini, L.; Coppola, D.; Hamilton, A.; Sebti, S.M. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. **Oncogene**. (Submitted)
193. Tang, D., Park, H., Sebti, S.M., Hamilton, A.D., Galper, J. HMG-CoA reductase inhibitors potentiate tumor necrosis factor  $\alpha$  mediated apoptosis of human vascular endothelial cells: role of increased expression of TNF $\alpha$  receptor 1. **Mol. Cancer Res.** (Submitted.)
194. McGuire, T., and Sebti, S.M. Geranylgeraniol and lovastatin: Synergistic (H-Ras) and antagonistic (K-Ras) interactions. **J. Biol. Chem.** (Manuscript in Preparation).
195. Blaskovich, M., Qian, Y., Hamilton, A.D. and Sebti, S.M. Effects of farnesyltransferase inhibitors on the association of Ras with phosphatidyl inositol 3-kinase. **J. Biol. Chem.** (Manuscript in Preparation).
196. Wei, S., Sun, J., Liu, J.H., Daulton, A., Sebti, S.M. and Djeu, J.Y. MAPK and PI-3K but not ras mediate GM-CSF-induced neutrophil survival. (Manuscript in Preparation).
197. Guida WC, Sebti SM, Hamilton AD, Crotty JW. Docking studies on protein farnesyltransferase inhibitors. **J. Comput. Aided Mol. Des.** (Manuscript in preparation).

CONFIDENTIAL

Saïd M. Sebti, Ph.D.

## ABSTRACTS

1. Sebti, S.M., Baird, W.M., Knowles, B. and Diamond, L. Binding of benzo(a)pyrene to the DNA of target cells in a cell-mediated mutation assay. Abstracts of the 7th International Symposium on Polynuclear Aromatic Hydrocarbons, Battelle Laboratories, Columbus, OH, p. 97, 1982.
2. Baird, W.M., Pruess-Schwartz, D., Sebti, S.M. and Gilham, P.T. Comparison of benzo(a)pyrene-DNA adducts formed in rodent embryo cell cultures and a human hepatoma cell line by immobilized boronate chromatography. Workshop in Carcinogenic Mechanisms in Cultured Human Tissue and Cells. Abstracts of the OLACC Oncology Conference, Ohio State University, 1984.
3. Pruess-Schwartz, D., Sebti, S.M. and Baird, W.M. Analysis of benzo(a)pyrene-DNA adducts by immobilized boronate chromatography. Proceedings of the American Association for Cancer Research, 25, p. 86, 1984.
4. Sebti, S.M., Pruess-Schwartz, D. and Baird, W.M. DNA interactions in rat embryo cell cultures. Proceedings of the American Association for Cancer Research, Toronto, Canada, 25, p. 86, 1984.
5. Sebti, S.M. and Baird, W.M. Benzo[a]pyrene-DNA adduct formation in V79 target cells in a Wistar rat embryo cell-mediated mutation assay. Abstracts of the 9th International Symposium on Polynuclear Aromatic Hydrocarbons, Battelle Laboratories, Columbus, OH, p. 78, 1984.
6. Sebti, S.M. and Lazo, J.S. Separation of pulmonary bleomycin hydrolase from pulmonary aminopeptidases. Proceedings of the Federation of American Societies for Experimental Biology, St. Louis, MO, 45, p. 4541, 1986.
7. Sebti, S.M. and Lazo, J.S. Purification and characterization of the protective enzyme, bleomycin hydrolase from rabbit lung. Proceedings of the American Association for Cancer Research, Los Angeles, CA, 27, p. 4, 1986.
8. Stone, K.L., Pati, U., Weissman, S., Sebti, S.M., Lazo, J.S. and Williams, K.R. Isolation and re-purification of picomole amounts of peptides on micropore HPLC columns. Proceedings of the American Society of Biological Chemists, Philadelphia, PA, 46, p. 2252, 1987.
9. Sebti, S.M., DeLeon, J.C., Hecht, S.M. and Lazo, J.S. Substrate specificity studies of bleomycin hydrolase. Proceedings of the American Association for Cancer Research, Atlanta, GA, 28, p. 5, 1987.
10. Sebti, S.M., DeLeon, J.C. and Lazo, J.S. Molecular and biochemical characteristics of purified rabbit pulmonary bleomycin hydrolase. Proceedings of the American Society of Biological Chemists, Philadelphia, PA, 46, p. 2231, 1987.
11. Lazo, J.S., Braun, I.D. and Sebti, S.M. Synergistic cytotoxicity with leupeptin and bleomycin-like compounds. Proceedings of the American Association for Cancer Research, New Orleans, LA, 29, p. 482, 1988.

12. Mignano, J.E., Sebti, S.M. and Lazo, J.S. Isolation and characterization of a partial-length cDNA clone for rabbit lung bleomycin (BLM) hydrolase. *The FASEB Journal*, 2, p.A1355, 1988.
13. Sebti, S. M., Jani, J. P. and Greenwood, D.C. Selective increased activity of cysteineproteinases cathepsin B and L in T24-H-ras-transformed murine cells. *Proceedings of the American Association for Cancer Research*, San Francisco, CA, 30, p. 427, 1989.
14. Sebti, S.M., Jani, J.P., Ovejera, A. and Gorelik, E. Cathepsin B, H and L activity levels in low and high metastatic variants of murine B16 melanoma. *Proceedings of the American Association for Cancer Research*, San Francisco, CA, 30, p. 90, 1989.
15. Mignano, J., Sebti, S.M. and Lazo, J.S. Characterization of partial length cDNA clone for bleomycin hydrolase reveals homology with the site of thiol protease, New Orleans, LA, *The FASEB Journal*, 3(4), p. 1146, 1989.
16. Sebti, S.M., Jani, J.P., Gorelik, E. and Lazo, J.S. Mechanism of resistance of human Burkitt lymphoma (Daudi) xenografts to bleomycin. *Proceedings of the American Association for Cancer Research*, Washington, D.C., 31, p. 352, 1990.
17. Jani, J.P., Mistry, J.S., Morris, G., Lazo, J.S. and Sebti, S.M. Sensitization of human colon carcinoma to bleomycin by the cysteine proteinase specific inhibitor, E-64. *Proceedings of the American Association for Cancer Research*, Houston, TX, 31, p. 372, 1991.
18. Mistry, J.S., Jani, J.P., Morris, G., Sebti, S.M. and Lazo, J.S. Synthesis and biological evaluation of a novel fluorescent analog of talisomycin S<sub>10b</sub>. *Proceedings of the American Association for Cancer Research*, Houston, TX, 31, p. 403, 1991.
19. Morris, G., Mistry, J.S., Jani, J.P., Sebti, S.M. and Lazo, J.S. Characterization of a non-neutralizing antibody to bleomycin hydrolase. *Proceedings of the American Association for Cancer Research*, Houston, TX, 32, p. 373, 1991.
20. Sebti, S.M., Tkalcovic, G.T. and Jani, J.P. Inhibition of tumor growth by lovastatin in nude mice bearing ras oncogene transformed cells. *Proceedings of the American Association for Cancer Research*, Houston, TX, 32, p. 82, 1991.
21. Mistry, J.S., Sebti, S.M. and Lazo, J.S. Fluoromycin: a probe for analyzing bleomycin-sensitive and resistant cells. Montpelier, France, 1991.
22. Calmels, T.P.G., Sebti, S.M. and Lazo, J.S. Genomic cloning of bleomycin hydrolase. *Proceedings of the American Association of Cancer Research*, San Diego, CA, 1992.
23. Morris, G., Mistry, J.S., Jani, J.P., Mignano, J.E., Sebti, S.M. and Lazo, J.S. Neutralization of bleomycin hydrolase by an epitope-specific antibody. *Proceedings of American Association of Cancer Research*, San Diego, CA, 1992.
24. Mistry, J.S., Jani, J.P., Sebti, S.M. and Lazo, J.S. Synthesis and evaluation of a novel fluorescent bleomycin analog. 23th National Medicinal Chemistry Symposium, Buffalo, NY, June, 1992.

25. Jani, J.P., Tkalcevic, G.T. and Sebti, S.M. Selective antitumor effect of lovastatin against H-*ras* as compared to *v-src* and *c-myc* oncogene-transformed cells. Proceedings of the American Association for Cancer Research, San Diego, CA, 1992.
26. Sebti, S.M. and Tkalcevic, G.T. Growth inhibition of *ras* oncogene-transformed cells by *ras* carboxyl terminal CAAX tetrapeptides. Proceedings of American Association of Cancer Research, San Diego, CA, 1992.
27. Jani, J.P., Mistry, J.S., Morris, G.M., Lazo, J.S. and Sebti, S.M. Overcoming human lung carcinoma resistance to bleomycin by the cysteine proteinase inhibitor, E-64. Proceedings of the American Association for Cancer Research. San Diego, CA, 1992.
28. McGuire, T., Corey, S. and Sebti, S.M. Lovastatin inhibits-insulin and PDGF-induced activation of phosphatidyl inositol 3-kinase. Proceedings of the American Association for Cancer Research. Orlando, FL, 1993.
29. Nigam, M., Seong, C., Blaskovich, M., Qian, Y., Hamilton, A. and Sebti, S.M. Potent inhibition of p21 *ras* farnesyl transferase with CAAX peptidomimetics. Proceedings of the American Association for Cancer Research. Orlando, FL, 1993.
30. Nigam, M., Seong, C., Blaskovich, M., McGuire, T., Qian, Y., Hamilton, A. and Sebti, S. Inhibition of p21 *ras* plasma membrane association and tumor growth by p21 *ras* CA<sub>1</sub>A<sub>2</sub>X peptidomimetics. Cell signaling and cancer treatments. El San Juan, Puerto Rico, 1993.
31. McGuire, T., Qian, Y., Blaskovich, M.A., Wathen, S., Marlowe, T., Vogt, A., Fossum, R., Corey, S., Hamilton, A. and Sebti, S.M. Ras CAAX mimics disrupt PDGF signaling events downstream as well as upstream of Ras. INSERM Conferences Philippe Laudat: The Biology of Ras and Ras-Related Proteins. Strasbourg, France. 1994.
32. Vogt, A., Qian, Y., Hamilton, A. and Sebti, S.M. Burkitt lymphoma Daudi cells contain two distinct farnesyltransferases with different sensitivities to Ras CAAX Peptidomimetic. Proceedings of the American Association for Cancer Research. Toronto, Canada, 1995.
33. Vogt, A., Qian, Y., Blaskovich, M., Fossum, R., Hamilton, A. and Sebti, S.M. Selective inhibition of farnesyltransferase and Ras processing by non-peptide Ras CAAX mimetics. Proceedings of the American Association for Cancer Research. Toronto, Canada, 1995.
34. McGuire, T., Qian, Y., Blaskovich, M., Wathen, S., Marlowe, T., Vogt, A., Fossum, R., Corey, S., Hamilton, A. and Sebti, S. Farnesyltransferase inhibitors disrupt PDGF signaling events downstream as well as upstream of Ras. Proceedings of the American Association for Cancer Research. Toronto, Canada, 1995.
35. Blaskovich, M., Qian, Y., Lerner, E., Fossum, R., McGuire, T., Hamilton, A. and Sebti, S.M. Ras CAAX peptidomimetics inhibit tumor growth in nude mice. Proceedings of the American Association for Cancer Research. Toronto, Canada, 1995.
36. Pei, Z. and Sebti, S. M. Yeast bleomycin hydrolase induces bleomycin resistance in mammalian cells. Proceedings of the American Association for Cancer Research. Toronto, Canada, 1995.

37. Qian, Y., Vogt, A., Sebti, S.M. and Hamilton, A.D. Non-peptide Ras-CAAX mimetic as selective inhibitors of Ras Farnesyltransferase. American Chemical Society Meeting. Chicago, IL, 1995.
38. Vogt, A., Qian, Y., Blaskovich, M.A., Hamilton, A.D., and Sebti, S.M. Design, synthesis and biological activity of non-peptide mimetic farnesyltransferase inhibitors as potential anti-cancer agents. Annual meeting of The German Pharmaceutical Society, Jena, Germany, 1995.
39. Boota, A., Johnson, B.A., Hamilton, A.D., Sebti, S.M. and Davies, P. Superoxide production by pulmonary microvascular smooth muscle cells is stimulated by IL-1 $\beta$  and PDGF and suppressed by Ras inhibitors. American Thoracic Society meeting. New Orleans, Louisiana, 1996.
40. Stark, S.W., Johnson, B.A., Hamilton, A.D., Sebti, S.M. and Davies, P. Ras inhibitors promote apoptosis in pulmonary microvascular smooth muscle cells. American Thoracic Society. New Orleans, Louisiana, 1996.
41. Finder, J., Sebti, S.M., Hamilton, A.D., Litz, J., Blaskovich, M. and Davies, P. Inhibition of Ras farnesylation reduces IL1 $\beta$ -stimulated iNOs in pulmonary artery smooth muscle cells. American Thoracic Society, New Orleans, Louisiana, 1996.
42. Bernhard, E.J., Kao, G., Bakanauskas, V., Knight, L. Cox, A.D., Sebti, S.M., Hamilton, A.D., Muschel, R.J. and McKenna, W.G. The farnesyltransferase inhibitor 277 can act as a radiosensitizer of cells expressing activated Ha-Ras. European Radiation Research Society - 44th Annual Meeting, Heidelberg, Germany, 1996.
43. Blaskovich, M., Qian, Y., Hamilton, A.D., and Sebti, S.M. Effects of farnesyltransferase (FTase) and geranylgeranyltransferase I (GGTase I) inhibitors on oncogenic H-Ras and K-Ras 4B interactions with phosphatidylinositol 3-Kinase. American Association for Cancer Research Annual Meeting, Washington, D.C., 1996.
44. Lerner, E., Qian, Y., Blaskovich, M., Fossum, R.D., Vogt, A., Sun, J., Cox, A., Der, C., Hamilton, A.D., and Sebti, S.M. Accumulation of inactive H-Ras/Raf complexes in the cytosol of cells treated with farnesyltransferase inhibitors. American Association for Cancer Research Annual Meeting, Washington, D.C., 1996.
45. McGuire, T., Qian, Y., Hamilton, A.D., and Sebti, S.M. PDGF receptor tyrosine phosphorylation, but not MAP kinase activation, requires protein geranylgeranylation. American Association for Cancer Research Annual Meeting, Washington, D.C., 1996.
46. Sun, J., Pei, Z., and Sebti, S.M. Stable expression of a 5' 400 bp anti-sense of the  $\beta$  subunit of farnesyltransferase in human lung carcinoma blocks oncogenic signaling in vitro and in vivo. American Association for Cancer Research Annual Meeting, Washington, D.C., 1996.
47. Vogt, A., Qian, Y., McGuire, T., Blaskovich, M.A., Hamilton, A.D., and Sebti, S.M. Selective inhibition of geranylgeranyltransferase-I (GGTase-I), not farnesyltransferase (FTase), arrests cells in G1. AACR Annual Meeting, Washington, D.C., 1996.



48. Pei, Z. and Sebti, S.M. Active site studies of bleomycin hydrolase by site-directed mutagenesis. American Association for Cancer Research Annual Meeting, Washington, D.C., 1996.
49. Bernhard, E.J., Kao, G., Cox, A.D., Sebti, S.M., Hamilton, A.D., McKenna, W.G., and Muschel, R.J. The farnesyl transferase inhibitor 277 can act as a radiosensitizer of cells expressing activated H-ras. American Association for Cancer Research Annual Meeting, Washington, D.C., 1996.
50. Sun, J., Qian, Y., Hamilton, A.D., and Sebti, S.M. The growth in nude mice by H-Ras and K-Ras 4B transformed cells is suppressed by farnesyltransferase and geranylgeranyltransferase I inhibitors, respectively. American Association for Cancer Research Annual Meeting, Washington, D.C., 1996.
51. Cox, A.D., Oldham, S.M., Der, C.J., Hamilton, A.D., Sebti, S.M. and Calkins, D.P. Inhibition of farnesyl transferase and geranylgeranyl transferase I in NIH fibroblast and RIE epithelial cells. American Association for Cancer Research Annual Meeting, Washington, D.C., 1996.
52. Lerner, E., Qian, Y., Hamilton, A.D., and Sebti, S.M. Suppression of oncogenic K-Ras 4B processing and signaling by a geranylgeranyltransferase-I inhibitor. American Association for Cancer Research Annual Meeting, Washington, D.C., 1996.
53. McGuire, T. and Sebti, S.M. Geranylgeraniol/lovastatin combination blocks the processing and signaling of oncogenic H-Ras but restores that of oncogenic K-Ras 4B. American Association for Cancer Research Annual Meeting, Washington, D.C., 1996.
54. Finder, J., Litz, J., Blaskovich, M., McGuire, T., Qian, Y., Hamilton, A., Davies, P., and Sebti, S.M. Inhibition of protein geranylgeranylation causes a superinduction of nitric oxide synthase-2 by IL-1B in vascular smooth muscle cells. American Thoracic Society Meeting, 1997.
55. Sun, J., Qian, Y., Hamilton, A.D., and Sebti, S.M. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for disruption of K-Ras prenylation but each alone is sufficient for inhibition of human tumor growth. The American Association of Cancer Research Annual Meeting, San Diego, California, 1997.
56. Yu, J. and Sebti, S.M. Identification of Ras/Raf complex disrupters from phase display peptide libraries. The American Association of Cancer Research Annual Meeting, San Diego, California, 1997.
57. Vogt, A., Qian, Y., Hamilton, A.D., and Sebti, S.M. Inhibition of protein geranylgeranylation arrests human tumor cells in G1 through a p53 independent induction of p21<sup>WAF1/CIP1/SDII</sup>. The American Association of Cancer Research Annual Meeting, San Diego, California, 1997.
58. Lerner, E.C., Zhang, T.T., Qian, Y., Hamilton, A.D., and Sebti, S.M. Inhibition of K-Ras but not H- or N-Ras prenylation requires both farnesyltransferase and geranylgeranyltransferase I inhibitors in human tumor cell lines. The American Association of Cancer Research Annual Meeting, San Diego, California, 1997.

59. Cohen-Jonathan, E., Monteil, S., Toulas, C. Daly-Schveitzer, N., Hamilton, A.D. Sebti, S.M. and Favre, G. Farnesylated protein is involved in radioresistance induced by the 24KDa basic fibroblast growth factor isoform in HeLa cells. The American Association of Cancer Research Annual Meeting, San Diego, California, 1997.
60. Bredel, M., Pollack, I.F., Freund, J.M., Hamilton, A.D. and Sebti, S.M. Peptidomimetic Inhibition of P21<sup>RAS</sup> Blocks the Proliferation of Malignant Gliomas and Induces Time-dependent Apoptosis. German Neurosurgical Society, April 1997.
61. Sebti, S.M. Prenyltransferase inhibitors, cell cycle and apoptosis: Implication for cancer and cardiovascular diseases. NATO Advanced Research Workshop, Clearwater Beach, Florida, December 1997.
62. Miquel, K., Pradines, A., Terce F., Hamilton, A.D., Sebti, S.M. and Favre, G. Protein Geranylgeranylation but not farnesylation controls G1/S transition and phosphatidylcholine biosynthesis in A549 human lung adenocarcinoma cells. NATO Advanced Research Workshop, Clearwater Beach, Florida, December 1997.
63. Bernhard, E.J., Hamilton, A.D., Sebti, S.M., Muschel, R.J. and McKenna, W.G. Prenyltransferase Inhibitors as Radiosensitizing Agents for Tumors Expressing Activated Ras. NATO Advanced Research Workshop, Clearwater Beach, Florida, December 1997.
64. Adnane, J., Qian, Y., Hamilton, A.D. and Sebti, S.M. p21WAF promoter is upregulated by the geranylgeranyltransferase-I inhibitor GGTI-298 through an Sp1-binding site. NATO Advanced Research Workshop, Clearwater Beach, Florida, December 1997.
65. Sun, J., Qian, Y., Hamilton, A.D. and Sebti, S.M. GGTI-298 blocks human tumor growth in G0/G1 by a mechanism involving induction of p21WAF, Rb hypophosphorylation and inhibition of cyclin-dependent kinases. NATO Advanced Research Workshop, Clearwater Beach, Florida, December 1997.
66. Lantry, L.E., Zhang, Z., Sebti, S., Hamilton A., Hu Z., Gao, F., Crist, K.A., Kelloff, G.J., Lubet, R.A., and You, M. Chemotherapeutic effect of the farnesyltransferase inhibitor FTI-276 on 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone induced tumorigenesis in A/J mouse lung. The American Association of Cancer Research Annual Meeting, New Orleans, LA, 1998.
67. Miquel, K., Pradines, A., Terce, F., Hamilton, A.D., Sebti, S.M. and Favre, G. Protein geranylgeranylation but not farnesylation control G1/S transition and phosphatidylcholine biosynthesis in A549 cells. The American Association of Cancer Research Annual Meeting, New Orleans, LA, 1998.
68. Sun, J., Knowles, D., Hamilton A.D. and Sebti, S.M. Antitumor activity of Non-thiol containing FTase Inhibitors. The American Association of Cancer Research Annual Meeting, New Orleans, LA, 1998.
69. Sun, Z., Qian, Y., Hamilton, A.D. and Sebti, S.M. GGTI-298 blocks human tumor growth in G0/G1 by a mechanism involving induction of the p21WAF, Rb hypophosphorylation and inhibition of cyclin-dependent kinases. The American Association of Cancer Research Annual

Meeting, New Orleans, LA, 1998.

70. Adnane, J., Qian, Y., Hamilton, A.D. and Sebti, S.M. P21WAF promoter is upregulated by the geranylgeranyltransferase-I inhibitor GGTI-298 through an Sp1-binding site. The American Association of Cancer Research Annual Meeting, New Orleans, LA, 1998.
71. Blaskovich, M.A., Wang, H., Hamilton, A.D. and Sebti, S.M. Selective inhibition of PDGF-dependent Receptor Tyrosine Phosphorylation and MAP Kinase Activation by Tryptophan Derivatives. The American Association of Cancer Research Annual Meeting, New Orleans, LA, 1998.
72. Epling-Burnette, P.K., Zhang, I., Chen, Z., Turkson, J., Jove, R. and Sebti, S.M. Identification of STAT3 binding peptides from a peptide phage display library. The American Association of Cancer Research Annual Meeting, New Orleans, LA, 1998.
73. Pollack, I.F., Bredel, M., Freund, J.M., and Sebti, S.M. Blockade of malignant glioma proliferation by inhibiting p21-Ras. The American Association of Cancer Research Annual Meeting, New Orleans, LA, 1998.
74. Bernhard, E.J., Wu, J.M., Hamilton, A.D., Sebti, S.M., Muschel, R.J. and McKenna, W.G. Prenyltransferase inhibitors as radiosensitizing agents for tumor cells with activated ras. The American Association of Cancer Research Annual Meeting, New Orleans, LA, 1998.
75. Mao W., Sun J., Hamilton A.D., Sebti S.M. and Yeatman T. Growth inhibition of colon cancer cells by FTase and GGTase inhibitors is associated with reduced Src kinase activity. Society of Surgical Oncology, San Diego, CA, 1998.
76. Sebti, S.M. and Hamilton, A.D. Inhibition of Protein Prenylation: A Novel Approach to Cancer and Cardiovascular Disease Therapy. 1999 Miami Nature Biotechnology Winter Symposia, Miami, Florida, 1999.
77. Turkson, J., Bowman, T., Adnane, J., Zhang, I., Sekharam, M., Wu, J., Sebti, S.M. and Jove, R. Cooperation between the Src Tyrosine Kinase and the Rac/Rho-regulated Serine/Threonine Kinases, p38/HOG and JNK/SAPK, in STAT3-mediated gene expression. 1999 Miami Nature Biotechnology Winter Symposia, Miami, Florida, 1999.
78. Chen, Z., Adnane, J., Munoz-Antonia, T., Bizouarn, F., Qian, Y., Hamilton, A.D. and Sebti, S.M. Inhibition of farnesyltransferase results in sensitization of human tumor cell lines to transforming growth factor  $\beta$ . Keystone Symposium, Santa Fe, New Mexico, 1999.
79. Benford, H.L., Helfrich, M.H., Hamilton, A.D., Sebti, S.M. and Rogers, M.J. Inhibition of protein geranylgeranylation by bisphosphonates and GGTI-298 causes activation of caspase 3-like proteases in osteoclasts. Keystone meeting on The Functions of Small GTPases, Santa Fe, NM, 1999 and Keystone meeting on Apoptosis and Programmed Cell Death, Breckenridge, 1999 and European Calcified Tissue Society Conference, Maastricht, 1999.
80. Coxon, F.P., Benford, H.L., Frith, J.C., Helfrich, M.H., van't Hof, R., Hamilton, A.D., Sebti, S.M., Luckman, S.P. and Rogers, M.J. Anti-resorptive Bisphosphonate Drugs Act by Inhibiting

Geranylgeranylation of Small GTP-binding Proteins. Keystone meeting on The Functions of Small GTPases, Santa Fe, NM, 1999 and Keystone meeting on Apoptosis and Programmed Cell Death, Breckenridge, 1999.

81. Coxon, F.P., Helfrich, M.H., van't Hof, R., Hamilton, A.D., Sebti, S.M. and Rogers, M.J. Geranylgeranylated proteins regulate osteoclast morphology, function and survival. European Calcified Tissue Society Conference, Maastricht, 1999.
82. Cohen-Jonathan, E., Muschel, R.J., McKenna, W.G., Hamilton, A.D., Sebti, S.M., Gibbs, J., Oliff, A., Cerniglia, G., Knight, L. and Bernhard, E.J. Farnesyltransferase-mediated radiosensitization of human tumor cell xenografts expressing mutant ras. The American Association of Cancer Research Annual Meeting, Philadelphia, PA, 1999.
83. Rosenberg, S.H., Alder, J., Bauch, J., Cherian, S.P., Cohen, J., Ewing, P., Hamilton, A.D., Henry, K.J., Marsh, K., Mitten, M., Ng, S.-C., Saeed, B., Sebti, S.M., Sorensen, B., Tasker, A.S., Wasicak, J.I. and Zhang, H. *In vitro* and *in vivo* activity of the farnesyltransferase inhibitor A-197574. The American Association of Cancer Research Ann. Mtg, Philadelphia, PA, 1999.
84. Brem, S., Duckworth, E., Obadia, M., Sun, J. and Sebti, S. Inhibitors of protein prenylation inhibit glioma and endothelial cell proliferation. The American Association of Cancer Research Annual Meeting, Philadelphia, PA, 1999.
85. Adnane, J., Bizouarn, F.A., Munoz-Antonia, T., Chen, Z., Qian, Y., Hamilton, A.D. and Sebti, S.M. Suppression of farnesyltransferase results in sensitization of human tumor cell lines to transforming growth factor beta. The American Association of Cancer Research Annual Meeting, Philadelphia, PA, 1999.
86. Blaskovich, M.A., Sun, J., Stanko, J., Palmer, J. and Sebti, S.M. CPA-NO-101, a cisplatin nitric oxide donor derivative, is a potent inhibitor of human tumor growth in nude mice. The American Association of Cancer Research Annual Meeting, Philadelphia, PA, 1999.
87. Blaskovich, M.A., Lin, Q., sun, J., Hamilton, A.D. and Sebti, S.M. RTKA-111, a selective antagonist of PDGF-dependent signaling, inhibits the growth of human tumors in vivo. The American Association of Cancer Research Annual Meeting, Philadelphia, PA, 1999.
88. Garcia, R., Sun, J., Minton, S., Kraker, A., Levitzki, A., Sebti, S.M. and Jove, R. Constitutive Activation of STAT3 Signaling by Src and JAK Tyrosine Kinases Regulates Growth of Human Breast Carcinoma Cells. The American Association of Cancer Research Annual Meeting, Philadelphia, PA, 1999.
89. Sun, J., Qian, Y., Chen, Z., Marfurt, J., Hamilton, A.D. and Sebti, S.M. Inhibition of protein geranylgeranylation results in partner switching of the cyclin-dependent kinase (CDK) inhibitors p27kip and p21waf from CDK-6 to CDK-2. The American Association of Cancer Research Annual Meeting, Philadelphia, PA, 1999.
90. Sun, J., Marfurt, J., Blaskovich, M.A., Bailey, R.D., Qian, Y., Hamilton, A.D. and Sebti, S.M. Effective combination therapy with the non-thiol farnesyltransferase inhibitor FTI-2148 and taxol, gemcitabine or cisplatin for human tumor xenografts in nude mice. The American

Association of Cancer Research Annual Meeting, Philadelphia, PA, 1999.

91. Bolick, S.C.E., Campbell, K., Hamilton, A., Sebti, S.M. and Dalton, W.S. Myeloma cells with activated N-Ras are sensitive to FTI-277. The American Association of Cancer Research Annual Meeting, Philadelphia, PA, 1999.
92. Turkson, J., Bowman, T., Adnane, J., Zhang, Y., Sekharam, M., Wu, J., Holzman, L., Frank, D., Sebti, S.M. and Jove, R. Requirement of Ras/Rac1-mediated p38 and JNK signaling for STAT3 transcriptional activity induced by the Src oncoprotein. Oncogene conference on Signal Transduction and Cell Cycle Regulation in Cancer, Frederick, MD, 1999.
93. Garcia, R., Sun, J., Bowman, T., Levitzki, A., Fujita, D., Moasser, M., Rosen, N., Parsons, S., Kraker, A., Sebti, S. and Jove, R. Constitutive activation of STAT3 signaling by Src and JAK tyrosine kinases regulates growth of human breast carcinoma cells. Oncogene conference on Signal Transduction and Cell Cycle Regulation in Cancer, Frederick, MD, 1999.
94. Jiang, K., Coppola, D., Crespo, N.C., Nicosia, S.V., Hamilton, A.D., Sebti, S.M. and Cheng, J.Q. Phosphatidylinositol 3-kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. 15<sup>th</sup> Annual Meeting on Oncogenes and Tumor Suppressors, Frederick MD, 1999.
95. Lin, Q., Blaskovich, M.A., Sun, J., Sebti, S.M. and Hamilton, A.D. Design, synthesis and biological evaluation of novel multi-loop ligands that selectively inhibit PDGF-dependent receptor tyrosine kinase signaling and human tumor growth in nude mice. 218<sup>th</sup> ACS National Meeting, MED100, New Orleans, LA, 1999.
96. Sebti, S.M. Farnesyltransferase Inhibitors in Lung Cancer Treatment: Important Translational Issues. 6<sup>th</sup> International Association for the Study of Lung Cancer, Lung Biology Workshop, Aspen, Colorado, 1999.
97. Iizuka, M., Shoichi, I., Hamilton, A. and Sebti, S. Effects of prenyltransferase inhibitors, FTI-277 and GGTI-298, on human lung cancer cells. Japan Society of Cancer Research and AACR-EORTC-NCI meeting on Molecular Targets and Cancer Therapeutics, Washington D.C. 1999.
98. Jiang, K., Coppola, D., Crespo, N.C., Nicosia, S.V., Hamilton, A.D., Cheng, J.Q. and Sebti, S.M. The farnesyltransferase inhibitor, FTI-277 targets the phosphatidylinositol 3-kinase/AKT2 pathway to induce apoptosis. AACR-NCI-EORTC meeting on Molecular Targets and Cancer Therapeutics, Washington D.C., 1999.
99. Sixou, S., Chouini, S., Hamilton, A., Sebti, S., Faye, J.C. and Favre G. FTI-277 prevents cell cycle progression and E2-induced progesterone receptor expression in MCF-7 cells. 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000.
100. Delord, J.P., Allal, C., Hamilton, A., Sebti, S., Favre, G. and Pradines, A. GGTI-298 induces G1 block and prevents the membrane localization of RhoA in early G1. 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000.
101. Cheng, J.Q., Jiang, K., Coppola, D., Crespo, N.C., Nicosia, S.V., Hamilton, A.D. and Sebti, S.M.

The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000.

100. Garcia, R., Sun, J., Bowman, T., Minton, S., Muro-Cacho, C., Ku, N.N., Cox, C., Falcone, R., Parsons, S., Kraker, A., Levitzki, A., Dalton, W., Sebti, S.M. and Jove, R. Constitutive activation of STAT3 signaling by Src and JAK tyrosine kinases regulates growth in human breast carcinoma cells. 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000.
101. Sun, J., Garcia, R., Yu, H., Heller, R., Niu, G., Coppola, D., Jove, R. and Sebti, S.M. Blocking STAT3 activation results in inhibition of tumor growth and induction of apoptosis in human breast and lung cancer cells. 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000.
102. Sebti, S.M., Jiang, K., Coppola, D., Crespo, N.C., Nicosia, S.V., Hamilton, A.D. and Cheng, J.Q. FTI-277, a farnesyltransferase inhibitor, induces apoptosis by blocking the phosphatidylinositol 3-kinase/AKT2 survival pathway in human cancer cells. 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000.
103. Sebti, S.M., Blaskovich, M.A., Lin, Q., Delarue, F., Sun, J., Coppola, D. and Hamilton, A.D. A platelet-derived growth factor binding molecule, GFB-111, inhibits angiogenesis and tumor growth of human tumors in mice. 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000.
104. Delarue, F. and Sebti, S.M. Ras and RhoA but not Rac1 suppress cytokine-induced NOS-2 transcription in human cancer cells. 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000.
105. Sun, J., Li, B., Lee, C.-S., Nam, S., Coppola, D., Hamilton, A.D., Dou, Q.P. and Sebti, S.M. The dipeptidyl proteasome inhibitor LCS-640 inhibits growth and induces apoptosis of the human lung adenocarcinoma A-549 xenografts in nude mice. 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000.
106. Crespo, N.C., Ohkanda, J., Hamilton, A.D. and Sebti, S.M. FTI-2153 inhibits progression through mitosis by accumulating cancer cells in prophase. 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000.
107. Chen, Z., Pradines, A., Favre, G. and Sebti, S.M. Farnesylated and geranylgeranylated RhoB suppress the transformation of Panc-1 human pancreatic cancer cells. 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000.
108. Jackson, R.J., Adnane, J.A., Nicosia, S.V., Pledger, W.J. and Sebti, S.M. Tumor Growth in p21 Knockout X ras Transgenic Mice. 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000.
109. Lantry, L.E., Zhang, Z., Wang, Y., Liu, G., Hamilton, A.D., Sebti, S.M., Kelloff, G.J., Lubet, R.A. and You, M. The farnesyltransferase inhibitor FTI-276 is chemopreventive for 4-(methyl-

nitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A.J. mice. 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000.

110. Wei, S., Gilvary, D.L., Corliss, B.C., Sebti, S.M., Sun, J., Straus, D.B., Leibson, P.J., Weber, M.J. and Djeu, J.Y. NK lysis of tumor cells: Requirement for a Ras-independent MAPK signal pathway. 91<sup>st</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000.
111. Sharpe, C.C., Dockrell, M.E.C., Noor, M.I., Hamilton, A.D., Sebti, S.M. and Hendry, B.M. Inhibition of post-translational modification of the Ras superfamily in renal fibroblasts. United Kingdom Renal Association, 2000.
112. Teng, S., Sun, J., Irby, R., Sebti, S. and Yeatman, T. V-Src transformation is mediated through farnesylated proteins. AAS 34<sup>th</sup> Meeting 2000
113. Crespo, N.C., Ohkanda, J., Hamilton, A.D. and Sebti, S.M. The farnesyltransferase inhibitor, FTI-2153, blocks proper bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. New Molecular Targets for Cancer Therapy, St. Petersburg Beach, FL, 2000.
114. Crespo, N.C., Sun, J., Ohkanda, J., Coppola, D., Cheng, J., Hamilton, A.D. and Sebti, S.M. The farnesyltransferase inhibitor, FTI-2148, inhibits tumor growth and induces apoptosis in vivo in OVCAR3 tumors, but not OVCAR3 tumors overexpressing Constitutively activated AKT-2. New Molecular Targets for Cancer Therapy, St. Petersburg Beach, FL, 2000.
115. Sun, J., Tang, J., Naidu, K.A., Nicosia, S.V., Sebti, S.M. and Coppola, D. Ascorbyl stearate inhibits proliferation, transformation, and induces apoptosis of human ovarian carcinoma cells. New Molecular Targets for Cancer Therapy, St. Petersburg Beach, FL, 2000.
116. Adnane, J., Seijo, E., Chen, Z., Bizouarn, F., Leal, M., Sebti, S.M. and Munoz-Antonia, T. Downregulation of TGF $\beta$  receptor II by the small GTPase RhoB. New Molecular Targets for Cancer Therapy, St. Petersburg Beach, FL, 2000.
117. Delarue, F.L. and Sebti, S.M. Ras and RhoA suppress whereas RhoB enhances cytokine-induced transcription of nitric oxide synthase II in human cancer cells. New Molecular Targets for Cancer Therapy, St. Petersburg Beach, FL, 2000.
118. Turkson, J., Chen, Z., Zhang, I., Hamilton, A.D., Sebti, S.M. and Jove, R. Small peptide inhibitors of STAT3 DNA-binding activity. New Molecular Targets for Cancer Therapy, St. Petersburg Beach, FL, 2000.
119. Adnane, J., Seijo, E., Chen, Z., Bizouarn, F., Leal, M., Sebti, S.M. and Munoz-Antonia, T. Transcriptional regulation by RhoB of the transforming growth factor  $\beta$  type II receptor. 92<sup>nd</sup> Annual Meeting of the American Association for Cancer Research, New Orleans, LA, 2001.
120. Blaskovich, M., Turkson, J., Jove, R. and Sebti, S.M. Discovery of a molecule that inhibits STAT3 activation: Development of a phospho STAT3 cyto blot high throughput assay. 92<sup>nd</sup> Annual Meeting of the American Association for Cancer Research, New Orleans, LA, 2001.

121. Adnane, J., Jackson, R., Nicosia, S., Cantor, A., Pledger, W.J. and Sebti, S.M. Loss of p21<sup>WAF1/CIP1</sup>, but not p27<sup>KIP1</sup>, accelerates mammary tumor onset and increases multiplicity in oncogenic H-Ras transgenic mice. 92<sup>nd</sup> Annual Meeting of the American Association for Cancer Research, New Orleans, LA, 2001.
122. Delarue, F., Taylor, B. and Sebti, S.M. Ras/MEK/Erk and Ras/RhoA suppress whereas RhoB enhances IL-1 $\beta$ -, TNF- $\alpha$ - and INF- $\gamma$ -stimulated nitric oxide synthase-2 expression. 92<sup>nd</sup> Annual Meeting of the American Association for Cancer Research, New Orleans, LA, 2001.
123. Sun, J., Adnane, J., Jackson, R., Ohkanda, J., Pledger, W.J., Hamilton, A.D. and Sebti, S.M. Loss of p21WAF1/CIP1 results in delayed FTI-2148-induced mammary tumor regression and accelerated tumor regrowth after FTI removal in an oncogenic H-Ras transgenic mouse model. 92<sup>nd</sup> Annual Meeting of the American Association for Cancer Research, New Orleans, LA, 2001.
124. Sun, J., Ohkanda, J., Adnane, J., Lockman, J., Hamilton, A.D. and Sebti, S.M. Geranylgeranyltransferase I (GGTase I) inhibitors induce mammary tumor regression in oncogenic H-Ras transgenic mice: Validation of GGTase I as a cancer therapy target. 92<sup>nd</sup> Annual Meeting of the American Association for Cancer Research, New Orleans, LA, 2001.
125. Crespo, N., Ohkanda, J., Yen, T., Hamilton, A.D. and Sebti, S.M. FTI-2153 inhibits bipolar spindle formation in human cancer cells: A mechanism for FTI-induced mitotic arrest. 92<sup>nd</sup> Annual Meeting of the American Association for Cancer Research, New Orleans, LA, 2001.
126. Crespo, N., Sun, J., Ohkanda, J., Cheng, J., Hamilton, A.D. and Sebti, S.M. Constitutively activated Akt-2 blocks the ability of FTI-2148 to inhibit the growth and to induce apoptosis of the human ovarian carcinoma OVCAR3 in nude mice. 92<sup>nd</sup> Annual Meeting of the American Association for Cancer Research, New Orleans, LA, 2001.
127. Adnane, J., Chen, Z., Ohkanda, J., Kothare, M., Hamilton, A.D. and Sebti, S.M. Upregulation of RhoB transcription, not inhibition of RhoB prenylation, as a potential mechanism by which farnesyltransferase and geranylgeranyltransferase I inhibitors suppress human tumor growth. 92<sup>nd</sup> Annual Meeting of the American Association for Cancer Research, New Orleans, LA, 2001.
128. Sun, J., Blaskovich, M., Lin, Q., Delarue, F., Park, H., Coppola, D., Hamilton, A.D. and Sebti, S. M. GFB-116, a vascular endothelial growth factor (VEGF) binder, inhibits tumor growth and angiogenesis. 92<sup>nd</sup> Annual Meeting of the American Association for Cancer Research, New Orleans, LA, 2001.
129. Savani, R.C., Zuman, A., DeLisser, H.M., Kucich, U., Abrams, W., Hamilton, A., Sebti, S. and Rosenbloom, J. A geranylgeranyltransferase I inhibitor limits bleomycin-induced pulmonary fibrosis. American Thoracic Society meeting, 2001.
130. Kalvin, D.M., Larsen, J.J., Swenson, R., Sowin, T., Augeri, D.J., Janowick, D., Henry, K.J., Wasicak, J., O'Connor, S., Sullivan, G., Tasker, A., Cohen, J., Sebti, S.M., Hamilton, A.D. and Rosenberg, S. Use of semi-automated and automated parallel solid-phase synthesis in the discovery of two novel non-thiol-containing peptidomimetic inhibitors of protein farnesyl



- transferase. 221<sup>st</sup> ACS Meeting, San Diego, CA, 2001.
131. Peng, H., Blaskovich, M.A., Sebti, S.M. and Hamilton, A.D. Synthesis and evaluation of potent, highly-selective inhibitors of protein geranylgeranyltransferase-I. 221<sup>st</sup> ACS Meeting, San Diego, CA, 2001.
  132. Kurzrock, R., Wilson, E.F. and Sebti, S.M. Clinical activity and inhibition of protein farnesylation in FTI-R115777 treated patients with myelodysplastic syndrome (MDS). Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2002.
  133. Delarue, F.L., Adnane, J., Bizouarn, F., Ohkanda, J., Hamilton, A.D. and Sebti, S.M. RhoB is transcriptionally induced by farnesyltransferase and geranylgeranyltransferase I inhibitors: Induction of RhoB does not correlate with human cancer cell growth inhibition. Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2002.
  134. Coppock, P., Blaskovich, M.A., Sun, J., Kenny, A. and Sebti, S.M. Discovery of Raf/MEK/ERK pathway inhibitors from the NCI Diversity Set using a phospho Erk1/2 antibody in a high throughput cytolot assay. Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2002.
  135. Blaskovich, M.A., Sun, J. and Sebti, S.M. Structure activity relationship studies of cucurbitacin derivatives identifies pharmacophores with potent anti-signaling activity targeting selectively constitutively-activated JAK2 and STAT3 tumor survival pathways. Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2002.
  136. Sun, J., Blaskovich, M.A., Delarue, F.L., Jain, R., Paris, D., Choi, K., Coppola, D., Mullan, M., Hamilton, A.D. and Sebti, S.M. GFB-116 inhibits VEGF activation of Flk-1 signal transduction and suppresses angiogenesis, tumorigenesis and metastasis. Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2002.
  137. Delarue, F.L., Adnane, J. and Sebti, S.M. K-Ras and c-myc cooperate to suppress RhoB promoter transcriptional activity. Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2002.
  138. Sebti, S.M., Adnane, J., Muro-Cacho, C., Mathews, L. and Munoz-Antonia, T. Suppression of RhoB expression in invasive carcinoma from head and neck cancer patients. Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2002.
  139. Blaskovich, M.A., Sun, J., Turkson, J., Jove, R. and Sebti, S.M. Discovery of JSI-124, a selective JAK/STAT3 signaling pathway inhibitor with potent antitumor activity against human cancer cells in nude mice. Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2002.
  140. Chen, Z., Wang, H-G and Sebti, S.M. RhoB binds RhoGDI-2, not RhoGDI-1, and inhibits its ability to promote colony formation of human pancreatic cancer cells. Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2002.
  141. Alsina, M., Overton, R., Belle, N., Wilson, E.F., Sullivan, D., Djulbegovic, B., Fonseca, R.,

- Dalton, W.S. and Sebti, S.M. Farnesyltransferase inhibitor FTI-R115777 is well tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2002.
142. Carrico, D., Gelb, M.H., Blaskovich, M.A., Sebti, S.M. and Hamilton, A.D. Design, synthesis and evaluation of peptidomimetic farnesyltransferase inhibitor ester pro-drugs as potent anti-parasitic agents. American Chemical Society, 2002.
143. Turkson, J. et al, "Novel Peptidomimetic inhibitors of Stat3 signaling and oncogenesis. EORTC-NCI-AACR, Frankfurt, Germany, 2002.
144. Epling-Burnette, P.K., Bai, F., Painter, J.S., Wei, S., Sebti, S.M., Djeu, J.Y. and Loughran, T.P. Survival Signals of Leukemic NK Cells Depend on the Activation of MAPK and Ras. 44<sup>th</sup> American Society of Hematology Annual Meeting, Philadelphia, PA, 2002.
145. Sebti, S.M., Thai, V., Peng, H., Carrico, D., Blaskovich, M.A., and Hamilton, A.D. The ability of geranylgeranyltransferase I inhibitors to induce G1 arrest is independent of Rb and expression levels of Erb1, 2, 3 and 4 in human breast cancer cell lines. Annual Meeting of the American Association for Cancer Research, Toronto, Canada 2003.
146. Sebti S.M., Paquette S., Kuhn J.G., Prados M., Robins H.I., DeAngelis L.M., Chang S.M., Schiff D., Wen P., Yung Y.K. A., Gilbert M., Find K., Greenberg H., Junck L., Abrey L.E., Lieberman F.S., Mehta M.P., Raizer J.J., Hess K., Cloughesy T.F. Inhibition of farnesyltransferase (not geranylgeranyltransferase I) enzyme activity and the processing of HDJ-2 (not Rap1) in peripheral blood monocytes of patients with recurrent malignant glioma treated with Zarnestra in phase I/II clinical trials. Annual Meeting of the American Association for Cancer Research, Toronto, Canada 2003.
147. Jiang K., Delarue F. and Sebti S.M. EGFR, ERBB2, Ras and Myc suppress RhoB promoter transcriptional activity. Annual Meeting of the American Association for Cancer Research, Toronto, Canada 2003.
148. Crespo N.C., Delarue F., Ohkanda J., Carrico D., Hamilton A.D. and Sebti S.M. Inhibitors of farnesyltransferase block bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Annual Meeting of the American Association for Cancer Research, Toronto, Canada 2003.
149. Sun J., Ohkanda J., Coppola D., Yin H., Kothare M., Busiglio B., Hamilton A.D. and Sebti S.M. Induction of breast carcinoma apoptosis and tumor regression in Ras transgenic mice treated with a geranylgeranyltransferase inhibitor. Annual Meeting of the American Association for Cancer Research, Toronto, Canada 2003.
150. Kurzrock R, Kantarjian HM, Cortes JE, Wright J, Wilson E, Sebti SM. Farnesyl protein transferase inhibitor (FTI) Zarnestra<sup>TM</sup> (R115777) in patients with myelodysplastic syndrome (MDS): Clinical and biological aspects. Myelodysplastic Syndrome Symposium, Paris, France 2003.

151. Carrico D, Pen H, Blaskovich M, Sebti SM, Hamilton A. Design, Synthesis and Biological Evaluation of Potent and Selective Peptidomimetic Geranylgeranyltransferase-I Inhibitors. ACS National Meeting, New York, September 2003.
152. Chakrabarti D, Patterson S, Pendyala P.R., Van Voorhis W.C., Gelb M, Hamilton A.D., Sebti, S.M., Allen, C.M. Mammalian Protein Farnesyltransferase Inhibitors Inhibit Growth and Protein Prenylation in *P. falciparum*. Woods Hole meeting, 2003.
153. Yang, L., Dan, H.C., Sun, M., Liu, Q., Sun, X-M, Nicosia, S.V., Feldman, R.I., Sebti, S.M. and Cheng, J.Q. Discovery of small molecule Akt inhibitor with antitumor activity in cancer cells overexpressing Akt. Annual Meeting of the American Association for Cancer Research, Orlando, Florida 2004.
154. Nefedova, Y., Lyn, D., Sebti, S.M. and Gabrilovich, D.I. A new selective Jak2/STAT3 pathway inhibitor JSI-124 improves dendritic cells differentiation in cancer. Annual Meeting of the American Association for Cancer Research, Orlando, Florida 2004.
155. Malafa, M.P., Louis, S., Donapaty, S.R., Horvath, E.M., Sebti, S.M. VEGF down regulation by Vitamin E Succinate involves inhibition of H-Ras signaling events in MDA MB 231. Annual Meeting of the American Association for Cancer Research, Orlando, Florida 2004.
156. Sun, J., Ohkanda, J., Coppola, D., Yin, H., Kothare, M., Busiglio, B., Hamilton, A.D. and Sebti, S.M. Geranylgeranyltransferase I inhibitor, GGTI-2154, induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. Annual Meeting of the American Association for Cancer Research, Orlando, Florida 2004.
157. Sebti, S.M., Paquette, S., Kuhn, J.G., Prados, M., Robins, H.I., DeAngelis, L.M., Chang, S.M., Schiff, D., Wen, P., Yung, W.K.A., Gilbert, M., Fink, K., Greenberg, H., Junck, L., Abrey, L.E., Lieberman, F.S., Mehta, M.P., Raizer, J.J., Hess, K., Cloughesy, T.F. The farnesyltransferase inhibitor Zarnestra suppresses protein farnesylation, not geranylgeranylation, in peripheral blood monocytes of patients with recurrent malignant glioma treated with Zarnestra in phase I/II clinical trials. Annual Meeting of the American Association for Cancer Research, Orlando, Florida 2004.
158. Jiang, K., Delarue, F. and Sebti, S.M. EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation. Annual Meeting of the American Association for Cancer Research, Orlando, Florida 2004.
159. xSun, J., Wang, D., Jain, R., Paquette, S., Ennis, E., Blaskovich, M., Baldini, L., Coppola, D., Hamilton, A.D. and Sebti, S.M. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Annual Meeting of the American Association for Cancer Research, Orlando, Florida 2004.
160. Jiang, K., Sun, J. and Sebti, S.M. Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion and metastasis. Annual Meeting of the American Association for Cancer Research, Orlando, Florida 2004.
161. Blaskovich, M., Bucher, C., Thai, V., Peng, H., Carrico, D., Moulder, S., Hamilton, A.D. and

Sebti, S.M. Geranylgeranyltransferase I inhibitors induce p27 accumulation and G1 arrest in human breast cancer cell lines independently of Rb status and expression levels of Erb1, 2, 3 and 4. Annual Meeting of the American Association for Cancer Research, Orlando, Florida 2004.

162. Epling-Burnette, P.K.; Wei, S.; Bai, Fanqi; Painter, J.S.; Sebti, S.M., Loughran Jr., T.P.; Djeu, J.Y. ERK Couples Chronic Survival of NK Cells to Constitutively-Activated Ras in Lymphoproliferative Disease of Granular Lymphocytes. 8<sup>th</sup> Annual Meeting of the Society for Natural Immunity and 20<sup>th</sup> International Natural Killer Cell Workshop, Noordwijkerhout, Netherlands 2004.